Condensed Statements of Comprehensive Income for the three monthsended

Condensed Statement of Changes in Stockholders' Equity for the threemonths ended

Condensed Statements of Cash Flows for the three months ended

Notes to Consolidated Financial Statements

Note 1 – Basis of Presentation

Note 2 – Critical Accounting Policies, Accounting Pronouncements Adopted

and Recently Issued Accounting Standards

Note 3 – Revenue from Contracts with Customers

Note 4 – Segment Data

Note 5 – Business Acquisitions

Note 6 – Fair ValueMeasurements

Note 7 – Debt

Note 8 – Income Taxes

Note 9 – Legal Proceedings

Note 10 – Stock-Based Compensation

Note 11 – Redeemable Noncontrolling Interests

Note 12 – Comprehensive Income

Note 13 – Plans of Restructuring

Note 14 – Earnings Per Share

Note 15 – Supplemental Cash Flow Information

Note 16 – Related Party Transactions

ITEM 2.

Management's Discussion and Analysis of

Financial Condition and Results of Operations

ITEM 3.

Quantitative and Qualitative Disclosures About Market Risk

ITEM 4.

Controls and Procedures

PARTII.OTHER INFORMATION

Unregistered Sales of Equity Securities and Use of Proceeds

See accompanying notes.

PART

~~PART~~ I. FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

HENRY SCHEIN, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in ~~thousands,~~millions,

except share data)

March 26,

December 25,

2022

2021

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents

126

118

Accounts receivable, net of reserves of $

and $

1,444

1,452

Inventories, net

1,871

1,861

Prepaid expenses and other

389

413

Total current assets

3,830

3,844

Property and equipment, net

358

366

Operating lease right-of-use assets

331

325

Goodwill

2,857

2,854

Other intangibles, net

644

668

Investments and other

427

424

Total assets

8,447

8,481

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable

914

1,054

Bank credit lines

Current maturities of long-term debt

Operating lease liabilities

Accrued expenses:

Payroll and related

326

385

Taxes

174

137

Other

561

593

Total current liabilities

2,144

2,307

Long-term debt

773

811

Deferred income taxes

Operating lease liabilities

277

268

Other liabilities

376

377

Total liabilities

3,610

3,805

Redeemable noncontrolling interests

613

Commitments and contingencies

(nil)

Stockholders' equity:

Preferred stock, $

0.01

par value,

1,000,000

shares authorized,

NaN

outstanding

Common stock, $

0.01

par value,

480,000,000

shares authorized,

137,708,809

outstanding on March 26, 2022 and

137,145,558

outstanding on December 25, 2021

Additional paid-in capital

Retained earnings

3,759

3,595

Accumulated other comprehensive loss

(168)

(171)

Total Henry Schein, Inc. stockholders' equity

3,592

3,425

Noncontrolling interests

632

638

Total stockholders' equity

4,224

4,063

Total liabilities, redeemable noncontrolling

interests and stockholders' equity

8,447

8,481

See accompanying notes.

HENRY SCHEIN, INC.

CONDENSED CONSOLIDATED STATEMENTS

OF INCOME

(unaudited, in millions, except share and per share data)

June 26,

December 26,

2021

2020

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents

$
167,228

$
421,185

Accounts receivable, net of reserves of $81,113 and $88,030

1,356,881

1,424,787

Inventories, net

1,688,210

1,512,499

Prepaid expenses and other

529,929

432,944

Total current assets

3,742,248

3,791,415
Property and equipment, net

358,224

342,004
Operating lease right-of-use assets

301,440

288,847
Goodwill

2,722,974

2,504,392
Other intangibles, net

604,515

479,429
Investments and other

394,665

366,445

Total assets

$
8,124,066

$
7,772,532

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable

$
903,859

$
1,005,655

Bank credit lines

72,105

73,366

Current maturities of long-term debt

9,839

109,836

Operating lease liabilities

75,008

64,716

Accrued expenses:

Payroll and related

313,892

295,329

Taxes

156,176

138,671

Other

562,762

595,529

Total current liabilities

2,093,641

2,283,102
Long-term debt

706,487

515,773
Deferred income taxes

46,528

30,065
Operating lease liabilities

243,232

238,727
Other liabilities

423,416

392,781

Total liabilities

3,513,304

3,460,448

Redeemable noncontrolling interests

604,081

327,699
Commitments and contingencies

Stockholders' equity:

Preferred stock, $0.01 par value, 1,000,000 shares authorized,

NaN outstanding

0

0

Common stock, $0.01 par value, 480,000,000 shares authorized,

139,780,841 outstanding on June 26, 2021 and

142,462,571 outstanding on December 26, 2020

1,398

1,425

Additional paid-in capital

0

0

Retained earnings

3,465,647

3,454,831

Accumulated other comprehensive loss

(106,779)

(108,084)

Total Henry Schein, Inc. stockholders' equity

3,360,266

3,348,172

Noncontrolling interests

646,415

636,213

Total stockholders' equity

4,006,681

3,984,385

Total liabilities, redeemable noncontrolling interests and stockholders' equity

$
8,124,066

$
7,772,532

Three Months Ended

March 26,

March 27,

2022

2021

Net sales

3,179

2,925

Cost of sales

2,206

2,034

Gross profit

973

891

Operating expenses:

Selling, general and administrative

682

614

Depreciation and amortization

Restructuring costs

Operating income

244

230

Other income (expense):

Interest income

Interest expense

(7)

(6)

Income before taxes, equity in earnings of affiliates and noncontrolling interests

239

226

Income taxes

(57)

Equity in earnings of affiliates

Net income

186

175

Less: Net income attributable to noncontrolling interests

(5)

(9)

Net income attributable to Henry Schein, Inc.

181

166

Earnings per share attributable to Henry Schein, Inc.:

Basic

1.31

1.17

Diluted

1.30

1.16

Weighted-average common

shares outstanding:

Basic

137,296,581

142,298,387

Diluted

139,237,472

143,397,724

See accompanying notes.

HENRY SCHEIN, INC.

CONDENSED CONSOLIDATED STATEMENTS

OF COMPREHENSIVE INCOME

(unaudited, in millions)

Three Months Ended

March 26,

March 27,

2022

2021

Net income

186

175

Other comprehensive income (loss), net of tax:

Foreign currency translation gain (loss)

(38)

Unrealized gain from foreign currency hedging activities

Pension adjustment gain

Other comprehensive income (loss), net of tax

(34)

Comprehensive income

190

141

Comprehensive income attributable to noncontrolling interests:

Net income

(5)

(9)

Foreign currency translation (gain) loss

(1)

Comprehensive income attributable to noncontrolling interests

(6)

(3)

Comprehensive income attributable to Henry Schein, Inc.

184

138

See accompanying notes.

HENRY SCHEIN, INC.

CONDENSED CONSOLIDATED ~~STATEMENTS~~ STATEMENT

OF ~~INCOME~~

CHANGES IN

STOCKHOLDERS’ EQUITY

(unaudited, in ~~thousands,~~millions, except ~~per~~ share data)

~~(unaudited)~~

Three Months Ended

Six Months Ended

June 26,

June 27,

June 26,

June 27,

2021

2020

2021

2020

Net sales

$
2,967,223

$
1,684,399

$
5,892,184

$
4,113,270
Cost of sales

2,077,472

1,230,133

4,111,582

2,912,990

Gross profit

889,751

454,266

1,780,602

1,200,280
Operating expenses:

Selling, general and administrative

678,801

445,765

1,336,793

1,013,127

Restructuring costs

604

15,934

3,535

20,721

Operating income (loss)

210,346

(7,433)

440,274

166,432
Other income (expense):

Interest income

1,357

1,997

3,340

5,187

Interest expense

(6,376)

(10,486)

(12,861)

(18,298)

Other, net

354

(291)

663

(511)

Income (loss) from continuing operations before taxes,

equity in earnings of affiliates and noncontrolling interests

205,681

(16,213)

431,416

152,810
Income tax benefit (expense)

(48,027)

950

(104,712)

(36,960)
Equity in earnings of affiliates

6,323

1,411

12,201

4,145
Net income (loss) from continuing operations

163,977

(13,852)

338,905

119,995
Income from discontinued operations, net of tax

0

585

0

303
Net income (loss)

163,977

(13,267)

338,905

120,298

Less: Net (income) loss attributable to noncontrolling interests

(8,261)

2,470

(17,192)

(834)

Plus: Net loss attributable to noncontrolling interests

from discontinued operations

0

0

0

0
Net income (loss) attributable to Henry Schein, Inc.

$
155,716

$
(10,797)

$
321,713

$
119,464
Amounts attributable to Henry Schein Inc.:

Continuing operations

$
155,716

$
(11,382)

$
321,713

$
119,161
Discontinued operations

0

585

0

303
Net income (loss) attributable to Henry Schein, Inc.

$
155,716

$
(10,797)

$
321,713

$
119,464

Earnings (loss) per share from continuing operations attributable to Henry Schein, Inc.:

Basic

$
1.11

$
(0.08)

$
2.28

$
0.84

Diluted

$
1.10

$
(0.08)

$
2.26

$
0.84

Earnings per share from discontinued operations attributable to Henry Schein, Inc.:

Basic

$
0

$
0

$
0

$
0

Diluted

$
0

$
0

$
0

$
0

Earnings (loss) per share attributable to Henry Schein, Inc.:

Basic

$
1.11

$
(0.08)

$
2.28

$
0.84

Diluted

$
1.10

$
(0.08)

$
2.26

$
0.84

Weighted-average common shares outstanding:

Basic

140,358

142,350

141,316

142,654

Diluted

141,657

142,350

142,538

142,654

Accumulated

Common Stock

Additional

Other

Total

$0.01 Par Value

Paid-in

Retained

Comprehensive

Noncontrolling

Stockholders'

Amount

Capital

Earnings

Income / (Loss)

Interests

Equity

Balance, December 25, 2021

137,145,558

3,595

(171)

638

4,063

Net income (excluding $

attributable to Redeemable

noncontrolling interests)

181

182

Foreign currency translation gain (excluding gain of $

attributable to Redeemable noncontrolling interests)

Unrealized gain from foreign currency hedging activities,

net of tax of $

Purchase of noncontrolling interests

(7)

Change in fair value of redeemable securities

(3)

Stock-based compensation expense

876,161

Stock issued upon exercise of stock options

26,233

Shares withheld for payroll taxes

(336,331)

(28)

Settlement of stock-based compensation awards

(2,812)

Transfer of charges in excess of

capital

(17)

Balance, March 26, 2022

137,708,809

3,759

(168)

632

4,224

Accumulated

Common Stock

Additional

Other

Total

$0.01 Par Value

Paid-in

Retained

Comprehensive

Noncontrolling

Stockholders'

Amount

Capital

Earnings

Income / (Loss)

Interests

Equity

Balance, December 26, 2020

142,462,571

3,455

(108)

636

3,984

Net income (excluding $

attributable to Redeemable

noncontrolling interests)

166

168

Foreign currency translation loss (excluding loss of $

attributable to Redeemable noncontrolling interests)

(32)

Unrealized gain from foreign currency hedging activities,

net of tax of $

Pension adjustment gain, net of tax of $

Change in fair value of redeemable securities

(46)

Initial noncontrolling interests and adjustments related

business acquisitions

Repurchase and retirement of common stock

(1,325,242)

(12)

(77)

(89)

Stock-based compensation expense

281,645

Settlement of stock-based compensation awards

Shares withheld for payroll taxes

(108,861)

(7)

Transfer of charges in excess of

capital

(51)

Balance, March 27, 2021

141,310,113

3,493

(136)

639

3,997

See accompanying notes.

HENRY SCHEIN, INC.

CONDENSED CONSOLIDATED STATEMENTS

OF CASH FLOWS

(unaudited, in millions)

Three Months Ended

March 26,

March 27,

2022

2021

Cash flows from operating activities:

Net income

186

175

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

Stock-based compensation expense

Provision for (benefit from) losses on trade and other accounts receivable

(3)

Provision for (benefit from) deferred income taxes

(3)

Equity in earnings of affiliates

(4)

(6)

Distributions from equity affiliates

Changes in unrecognized tax benefits

Other

(7)

Changes in operating assets and liabilities, net of acquisitions:

Accounts receivable

119

Inventories

(9)

(78)

Other current assets

(45)

Accounts payable and accrued expenses

(188)

(180)

Net cash provided by operating activities

Cash flows from investing activities:

Purchases of fixed assets

(19)

(14)

Payments related to equity investments and business

acquisitions, net of cash acquired

(5)

(204)

Proceeds from loan to affiliate

Other

(7)

(5)

Net cash used in investing activities

(27)

(223)

Cash flows from financing activities:

Net change in bank borrowings

Principal payments for long-term debt

(53)

(18)

Proceeds from issuance of stock upon exercise of stock options

Payments for repurchases and retirement of common stock

(89)

Payments for taxes related to shares withheld for employee taxes

(26)

(6)

Distributions to noncontrolling shareholders

(5)

(7)

Acquisitions of noncontrolling interests in subsidiaries

(10)

Net cash used in financing activities

(62)

(120)

Effect of exchange rate changes on cash and cash equivalents

Net change in cash and cash equivalents

(277)

Cash and cash equivalents, beginning of period

118

421

Cash and cash equivalents, end of period

126

144

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

~~CONSOLIDATED~~FINANCIAL STATEMENTS ~~OF COMPREHENSIVE INCOME~~

(in ~~thousands)~~

~~(unaudited)~~

Three Months Ended

Six Months Ended

June 26,

June 27,

June 26,

June 27,

2021

2020

2021

2020

Net income (loss)

$
163,977

$
(13,267)

$
338,905

$
120,298

Other comprehensive income (loss), net of tax:

Foreign currency translation gain (loss)

38,138

34,408

(343)

(54,904)

Unrealized gain (loss) from foreign currency hedging

activities

(1,751)

(4,989)

1,610

10,154

Unrealized investment gain (loss)

3

2

(3)

(7)

Pension adjustment gain (loss)

35

(225)

842

499

Other comprehensive income (loss), net of tax

36,425

29,196

2,106

(44,258)
Comprehensive income

200,402

15,929

341,011

76,040

Comprehensive income attributable to noncontrolling

interests:

Net (income) loss

(8,261)

2,470

(17,192)

(834)

Foreign currency translation (gain) loss

(6,899)

(799)

(801)

12,380

Comprehensive (income) loss attributable to noncontrolling

interests

(15,160)

1,671

(17,993)

11,546

Comprehensive income attributable to Henry Schein, Inc.

$
185,242

$
17,600

$
323,018

$
87,586

~~See accompanying notes.~~

~~HENRY SCHEIN, INC.~~

~~CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY~~

~~(in thousands,~~millions, except share and per share data)

~~(unaudited)~~

Accumulated

Common Stock
Additional

Other

Total

$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'

Shares

Amount
Capital
Earnings
Income / (Loss)
Interests
Equity
Balance, March 27, 2021
141,310,113
$
1,413
$
0
$
3,493,060
$
(136,305)
$
638,562
$
3,996,730
Net income (excluding $6,980 attributable to Redeemable

noncontrolling interests from continuing operations)
-

0

0

155,716

0

1,281

156,997
Foreign currency translation gain (excluding gain of $6,743

attributable to Redeemable noncontrolling interests)
-

0

0

0

31,239

156

31,395
Unrealized loss from foreign currency hedging activities,

net of tax benefit of $687
-

0

0

0

(1,751)

0

(1,751)
Unrealized investment gain, net of tax of $1
-

0

0

0

3

0

3
Pension adjustment gain, net of tax benefit of $38
-

0

0

0

35

0

35
Dividends paid
-

0

0

0

0

(77)

(77)
Change in fair value of redeemable securities
-

0

(87,188)

0

0

0

(87,188)
Initial noncontrolling interests and adjustments related to

business acquisitions
-

0

0

0

0

6,493

6,493
Repurchase and retirement of common stock
(1,542,315)

(15)

(14,992)

(97,545)

0

0

(112,552)
Stock-based compensation expense
17,916

0

17,364

0

0

0

17,364
Shares withheld for payroll taxes
(4,873)

0

(369)

0

0

0

(369)
Settlement of stock-based compensation awards
-

0

(399)

0

0

0

(399)
Transfer of charges in excess of capital
-

0

85,584

(85,584)

0

0

0
Balance, June 26, 2021
139,780,841
$
1,398
$
0
$
3,465,647
$
(106,779)
$
646,415
$
4,006,681

Accumulated

Common Stock
Additional

Other

Total

$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'

Shares

Amount
Capital
Earnings
Income / (Loss)
Interests
Equity
Balance, March 28, 2020
142,433,360
$
1,424
$
17,565
$
3,183,236
$
(227,648)
$
631,215
$
3,605,792
Net loss (excluding loss of $1,678 attributable to Redeemable

noncontrolling interests from continuing operations)
-

0

0

(10,797)

0

(792)

(11,589)
Foreign currency translation gain (excluding gain of $751

attributable to Redeemable noncontrolling interests)
-

0

0

0

33,609

48

33,657
Unrealized loss from foreign currency hedging activities,

net of tax benefit of $1,744
-

0

0

0

(4,989)

0

(4,989)
Unrealized investment gain, net of tax of $1
-

0

0

0

2

0

2
Pension adjustment loss, net of tax benefit of $125
-

0

0

0

(225)

0

(225)
Dividends paid
-

0

0

0

0

(8)

(8)
Purchase of noncontrolling interests
-

0

0

0

0

(9)

(9)
Change in fair value of redeemable securities
-

0

(7,489)

0

0

0

(7,489)
Initial noncontrolling interests and adjustments related to

business acquisitions
-

0

0

0

0

4

4
Stock-based compensation expense
7,033

0

5,156

0

0

0

5,156
Shares withheld for payroll taxes
(2,266)

0

(132)

0

0

0

(132)
Settlement of stock-based compensation awards
-

0

(273)

0

0

0

(273)
Separation of Animal Health business
-

0

1,648

0

0

0

1,648
Balance, June 27, 2020
142,438,127
$
1,424
$
16,475
$
3,172,439
$
(199,251)
$
630,458
$
3,621,545

~~See accompanying notes.~~

~~HENRY SCHEIN, INC.~~

~~CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY~~

(~~in thousands, except share and per share data)~~

~~(unaudited)~~

Accumulated

Common Stock
Additional

Other

Total

$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'

Shares

Amount
Capital
Earnings
Income / (Loss)
Interests
Equity
Balance, December 26, 2020
142,462,571
$
1,425
$
0
$
3,454,831
$
(108,084)
$
636,213
$
3,984,385
Net income (excluding $14,033 attributable to Redeemable

noncontrolling interests from continuing operations)
-

0

0

321,713

0

3,159

324,872
Foreign currency translation gain (loss) (excluding gain of $570

attributable to Redeemable noncontrolling interests)
-

0

0

0

(1,144)

231

(913)
Unrealized gain from foreign currency hedging activities,

net of tax of $647
-

0

0

0

1,610

0

1,610
Unrealized investment loss, net of tax benefit of $1
-

0

0

0

(3)

0

(3)
Pension adjustment gain, net of tax of $181
-

0

0

0

842

0

842
Dividends paid
-

0

0

0

0

(154)

(154)
Change in fair value of redeemable securities
-

0

(132,708)

0

0

0

(132,708)
Initial noncontrolling interests and adjustments related to

business acquisitions
-

0

0

0

0

6,966

6,966
Repurchase and retirement of common stock
(2,867,557)

(29)

(27,241)

(173,941)

0

0

(201,211)
Stock-based compensation expense
299,561

3

30,151

0

0

0

30,154
Shares withheld for payroll taxes
(113,734)

(1)

(7,546)

0

0

0

(7,547)
Settlement of stock-based compensation awards
0

0

388

0

0

0

388
Transfer of charges in excess of capital
-

0

136,956

(136,956)

0

0

0
Balance, June 26, 2021
139,780,841
$
1,398
$
0
$
3,465,647
$
(106,779)
$
646,415
$
4,006,681

Accumulated

Common Stock
Additional

Other

Total

$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'

Shares

Amount
Capital
Earnings
Income / (Loss)
Interests
Equity
Balance, December 28, 2019
143,353,459
$
1,434
$
47,768
$
3,116,215
$
(167,373)
$
632,093
$
3,630,137
Cumulative impact of adopting new accounting standards
-

0

0

(412)

0

0

(412)
Net income (excluding $1,161 attributable to Redeemable

noncontrolling interests from continuing operations)
-

0

0

119,464

0

(327)

119,137
Foreign currency translation loss (excluding loss of $12,276

attributable to Redeemable noncontrolling interests)
-

0

0

0

(42,524)

(104)

(42,628)
Unrealized gain from foreign currency hedging activities,

net of tax of $3,346
-

0

0

0

10,154

0

10,154
Unrealized investment loss, net of tax benefit of $1
-

0

0

0

(7)

0

(7)
Pension adjustment gain, net of tax of $199
-

0

0

0

499

0

499
Dividends paid
-

0

0

0

0

(507)

(507)
Purchase of noncontrolling interests
-

0

(1,597)

0

0

(701)

(2,298)
Change in fair value of redeemable securities
-

0

5,583

0

0

0

5,583
Initial noncontrolling interests and adjustments related to

business acquisitions
-

0

0

0

0

4

4
Repurchase and retirement of common stock
(1,200,000)

(12)

(10,949)

(62,828)

0

0

(73,789)
Stock-based compensation expense (credit)
514,443

5

(12,363)

0

0

0

(12,358)
Shares withheld for payroll taxes
(229,775)

(3)

(14,003)

0

0

0

(14,006)
Settlement of stock-based compensation awards
0

0

387

0

0

0

387
Separation of Animal Health business
-

0

1,649

0

0

0

1,649
Balance, June 27, 2020
142,438,127
$
1,424
$
16,475
$
3,172,439
$
(199,251)
$
630,458
$
3,621,545
unaudited

~~See accompanying notes.~~

)

~~HENRY SCHEIN, INC.~~

~~CONSOLIDATED STATEMENTS OF CASH FLOWS~~

~~(in thousands)~~

~~(unaudited)~~

Six Months Ended

June 26,

June 27,

2021

2020
Cash flows from operating activities:

Net income

$
338,905

$
120,298

Income from discontinued operations

0

303

Income from continuing operations

338,905

119,995

Adjustments to reconcile net income to net cash provided by (used in) operating activities:

Depreciation and amortization

99,278

93,946

Impairment charge on intangible assets

0

2,149

Stock-based compensation expense (credit)

30,154

(12,358)

Provision for (benefit from) losses on trade and other accounts receivable

(4,072)

28,758

Provision (benefit from) for deferred income taxes

5,705

(32,871)

Equity in earnings of affiliates

(12,201)

(4,145)

Distributions from equity affiliates

10,747

4,220

Changes in unrecognized tax benefits

(6,286)

1,380

Other

3,429

227

Changes in operating assets and liabilities, net of acquisitions:

Accounts receivable

101,619

99,672

Inventories

(123,758)

13,700

Other current assets

(85,979)

(188,616)

Accounts payable and accrued expenses

(135,815)

(138,900)
Net cash provided by (used in) operating activities from continuing operations

221,726

(12,843)
Net cash provided by operating activities from discontinued operations

0

573
Net cash provided by (used in) operating activities

221,726

(12,270)

Cash flows from investing activities:

Purchases of fixed assets

(31,812)

(30,588)

Payments related to equity investments and business

acquisitions, net of cash acquired

(295,652)

(37,725)

Proceeds from sale of equity investment

0

12,000

Payments for loan to affiliate

(2,021)

(1,729)

Other

(11,634)

(11,599)
Net cash used in investing activities from continuing operations

(341,119)

(69,641)
Net cash used in investing activities from discontinued operations

0

0
Net cash used in investing activities

(341,119)

(69,641)

Cash flows from financing activities:

Net change in bank borrowings

(5,381)

479,702

Proceeds from issuance of long-term debt

200,000

501,421

Principal payments for long-term debt

(120,326)

(609,580)

Debt issuance costs

(199)

(3,655)

Payments for repurchases of common stock

(201,211)

(73,789)

Payments for taxes related to shares withheld for employee taxes

(7,359)

(13,713)

Distributions to noncontrolling shareholders

(3,789)

(3,466)

Acquisitions of noncontrolling interests in subsidiaries

(1,130)

(14,934)

Proceeds from Henry Schein Animal Health Business

0

64
Net cash provided by (used in) financing activities from continuing operations

(139,395)

262,050
Net cash used in financing activities from discontinued operations

0

(573)
Net cash provided by (used in) financing activities

(139,395)

261,477
Effect of exchange rate changes on cash and cash equivalents from continuing operations

4,831

10,447
Effect of exchange rate changes on cash and cash equivalents from discontinued operations

0

0
Net change in cash and cash equivalents from continuing operations

(253,957)

190,013
Net change in cash and cash equivalents from discontinued operations

0

0
Cash and cash equivalents, beginning of period

421,185

106,097
Cash and cash equivalents, end of period

$
167,228

$
296,110

~~See accompanying notes.~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

Note 1 – Basis of Presentation

Our condensed consolidated financial statements include ~~our~~the accounts ~~as well as those~~of Henry

Schein, Inc. and all of our ~~wholly-owned~~

controlled subsidiaries.

All intercompany accounts and ~~majority-owned subsidiaries.~~ transactions are eliminated

in consolidation.

Investments

in unconsolidated affiliates in which we have the ability to influence the operating

or financial decisions are

accounted for under the equity method.

Certain prior period amounts have been reclassified to conform

to the

current period presentation.

Our accompanying unaudited condensed consolidated financial statements

have been prepared in accordance with

accounting principles generally accepted in the United States (“

(“U.S. GAAP”) for interim financial information and

with the instructions to Form 10-Q and Article 10 of Regulation S-X.

Accordingly, they do not include all of the

information and footnote disclosures required by U.S. GAAP for complete financial

statements.

~~We consolidate a Variable Interest Entity (“VIE”) where we hold a variable interest and are the primary beneficiary.~~

The VIE is a trade accounts receivable securitization. We are the primary beneficiary because we have the power to direct activities that most significantly affect the economic performance and have the obligation to absorb the majority of the losses or benefits. The results of operations and financial position of this VIE are included in our consolidated financial statements.

For the consolidated VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. At June 26, 2021 and December 26, 2020, there were 0 trade accounts receivable that were restricted to settle obligations of this VIE, 0r were there liabilities of the VIE where the creditors have recourse to us.

~~The~~unaudited interim condensed consolidated financial statements should be

read in conjunction with the audited

consolidated financial statements and notes to the consolidated financial

statements contained in our Annual Report

on Form 10-K for the year ended December 25, 2021 and with the information

contained in our other publicly-

available filings with the Securities and Exchange Commission.

The condensed consolidated financial statements

reflect all adjustments considered necessary for a fair presentation of the

consolidated results of operations and

financial position for the interim periods presented.

All such adjustments are of a normal recurring nature. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 26, 2020.

The preparation of financial statements in conformity with accounting principles

generally accepted in the United

States requires us to make estimates and assumptions that affect the reported amounts of

assets and liabilities and

disclosure of contingent assets and liabilities at the date of the financial statements

and the reported amounts of

revenues and expenses during the reporting period.

Actual results could differ from those estimates.

The results of

operations for the ~~six~~three months ended ~~June~~March 26, ~~2021~~2022 are not necessarily

indicative of the results to be expected

for any other interim period or for the year ending December 31, 2022.

We consolidate the results of operations and financial position of a trade accounts receivable securitization which

we consider a Variable Interest Entity (“VIE”) because we are the primary beneficiary, and we have the power to

direct activities that most significantly affect the economic performance and have

the obligation to absorb the

majority of the losses or benefits.

For this VIE, the trade accounts receivable transferred to the VIE are

pledged as

collateral to the related debt.

The creditors have recourse to us for losses on these trade accounts

receivable.

March 26, 2022 and December 25, ~~2021.~~

~~In March 2020,~~2021, certain trade accounts receivable

that can only be used to settle

obligations of this VIE were $

million and $

138

million, respectively, and the ~~World Health Organization declared~~liabilities of this VIE where the ~~Novel Coronavirus Disease 2019 (“COVID-19”) a pandemic. The COVID-19 pandemic negatively impacted the global economy, disrupted global supply chains~~

creditors have recourse to us were $

million and created significant volatility and disruption of global financial markets. In response, many countries implemented business closures and restrictions, stay-at-home and social distancing ordinances and similar measures to combat the pandemic, which significantly impacted global business and dramatically reduced demand for dental products and certain medical products in the second quarter of 2020.Demand increased in the second half of 2020 and has continued into the first half of 2021, resulting in growth over the prior year driven by sales of personal protective equipment (PPE) and COVID-19 related products.

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

105

million, respectively.

Our condensed consolidated financial statements reflect estimates and assumptions

made by us that affect, among

other things, our goodwill, long-lived asset and definite-lived intangible

asset valuation; inventory valuation; equity

investment valuation; assessment of the annual effective tax rate; valuation of deferred

income taxes and income

tax contingencies; the allowance for doubtful accounts; hedging activity; ~~vendor~~

supplier rebates; measurement of

compensation cost for certain share-based performance awards and cash bonus

plans; and pension plan

assumptions.

Due to the significant uncertainty surrounding the future impact of

COVID-19, our judgments

regarding estimates and impairments could change in the ~~future. In addition, the impact of COVID-19 had a material adverse effect on our business, results of operations~~future and cash flows, primarily in the second quarter of 2020. In the latter half of the second quarter of 2020, dental and medical practices began to re-open worldwide, and continued to do so during the second half of 2020. During the first half of 2021, patient traffic levels returned to levels approaching pre-pandemic levels. There is an ongoing risk that the COVID-19 pandemic may again have a material adverse effect on our business, results of operations and cash flows and

may result in a material adverse effect on our

financial condition and liquidity.

However, the extent of the potential impact cannot be reasonably estimated at this ~~time.~~

time.

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in millions, except share and per share data)

(unaudited

)

Note 2 – Critical Accounting Policies, Accounting Pronouncements Adopted

and Recently Issued Accounting

Standards

Critical Accounting Policies

There have been no material changes in our critical accounting policies

during the ~~six~~three months ended ~~June~~March 26, ~~2021,~~

2022, as compared to the critical accounting policies described in Item ~~8 to the consolidated financial statements included in~~

7 of our Annual Report on Form 10-K for

the year ended December ~~26, 2020,~~25, 2021, except as follows:

Accounting Pronouncements Adopted

December 26, 2021

we adopted Accounting Standards Update (“ASU”) No. 2021 – 08, “Accounting

for

Contract Assets and Contract Liabilities from Contracts with Customers”

(Subtopic 805), as early adoption of this

ASU was permitted.

ASU 2021 – 08 requires an acquirer to recognize and measure

contract assets and contract

liabilities acquired in a business combination in accordance with Topic 606.

At the acquisition date, an acquirer

should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts.

To achieve this, an acquirer may assess how the acquiree applied Topic 606 to determine what to record for the

acquired revenue contracts.

Generally, this should result in an acquirer recognizing and measuring the acquired

contract assets and contract liabilities consistent with how

they were recognized and measured in the acquiree’s

financial statements.

Our

adoption

of ASU 2021 - 08 did not have a material impact on our consolidated

financial

statements.

Recently Issued Accounting Standards

In ~~December 2019~~,March 2020, the Financial Accounting Standards Board (“FASB”) issued ~~Accounting Standards Update~~ASU No. 2020-04, “Reference Rate

Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting” which provides

optional expedients and exceptions for applying U.S. GAAP to contracts,

hedging relationships and other

transactions affected by the discontinuation of the London Interbank Offered Rate (“~~ASU”~~LIBOR”) ~~No. 2019-12, “Income Taxes”~~or

by another

reference rate expected to be discontinued because of reference rate reform.

The guidance was effective beginning

March 12, 2020 and can be applied prospectively through December 31,

2022.

In January 2021, the FASB issued

ASU 2021-01, Reference Rate Reform (Topic ~~740)~~848): ~~Simplifying the Accounting for Income Taxes~~Scope (“ASU ~~2019-12”~~2021-01”).

ASU ~~2019-12 will simplify the accounting for income taxes by removing certain~~2021-01 provides temporary

optional expedients and exceptions to ~~the general principles~~certain guidance in ~~Topic 740. The amendments also improve consistent application of and simplify~~ U.S. GAAP ~~for~~

to ease the financial reporting burdens related

to the expected market transition from LIBOR and other ~~areas~~interbank offered rates

to alternative reference rates, such

as the Secured Overnight Financing Rate.

The guidance is effective upon issuance, on January 7, 2021, and can be

applied through December 31, 2022.

We do not expect that the requirements of ~~Topic 740 by clarifying and amending existing guidance. Our~~ ~~adoption of ASU 2019-12 did not~~this guidance will have a material

impact on our consolidated financial statements.

~~Recently Issued Accounting Standards~~

In ~~August 2020,~~March 2022, the FASB issued ASU No. ~~2020-06, “Debt—Debt with Conversion and Other Options” (Subtopic 470-20) and~~2022-01, “Derivatives and ~~Hedging—~~Hedging (Topic 815): Fair Value

Hedging –

Portfolio Layer Method,” which will expand companies' abilities

to hedge the benchmark interest rate risk of

portfolios of financial assets (or beneficial interests) in ~~Entity’s Own Equity” (Subtopic 815-40): Accounting~~a fair value hedge.

This ASU expands the use of the

portfolio layer method (previously referred to as the last-of-layer

method) to allow multiple hedges of a single

closed portfolio of assets using spot starting, forward starting and amortizing-notional

swaps.

It also permits both

prepayable and non-prepayable financial assets to be included in the closed

portfolio of assets hedged in a portfolio

layer hedge.

This ASU further requires that basis adjustments not be allocated

to individual assets for ~~Convertible Instruments and Contracts in an Entity’s Own Equity (“~~active

portfolio layer method hedges, but rather be maintained on the closed portfolio

of assets as a whole.

ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible instruments. In addition to eliminating certain accounting models, this ASU includes improvements to the disclosures for convertible instruments and earnings-per-share (EPS) guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity. ASU 2020-062022 –

01 is effective for fiscal years beginning after December 15, ~~2021.~~ 2022, including interim periods

within those fiscal

years.

Early adoption is permitted for any entity that has adopted the amendments

in ASU 2017-12.

We do not

expect that the requirements of this guidance will have a material impact

on our consolidated financial statements.

In March 2022, the FASB issued ASU No. 2022-02, “Financial Instruments – Credit Losses (Topic 326): Troubled

Debt Restructuring and Vintage Disclosures”.

The amendments in this ASU eliminate the accounting guidance

for

troubled debt restructurings by creditors that have adopted the Current Expected

Credit Losses model and enhance

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in millions, except share and per share data)

(unaudited

)

the disclosure requirements for loan refinancings and restructurings

made with borrowers experiencing financial

difficulty.

In addition, the amendments require a public business entity

to disclose current-period gross write-offs

for financing receivables and net investment in leases by year of origination

in the vintage disclosures.

ASU 2022

– 02 is effective for fiscal years beginning after December 15, 2022, including

interim periods within those fiscal

years.

Early adoption is permitted for any entity that has adopted the amendments

in ASU No. 2016-13, “Financial

Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”.

We do not

expect that the requirements of this guidance will have a material impact on our

consolidated financial statements.

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

Note 3 – Revenue from Contracts with Customers

Revenue is recognized in accordance with policies disclosed in Item 8 of our

Annual Report on Form 10-K for

the year ended December ~~26, 2020.~~

25, 2021.

Disaggregation of ~~Revenue~~

Net Sales

The following table disaggregates our ~~revenue~~Net sales by reportable segment and ~~geography:~~

Three Months Ended

Six Months Ended

June 26, 2021

June 26, 2021

North America

International

Global

North America

International

Global
Revenues:

Health care distribution

Dental
$
1,127,607

$
782,737

$
1,910,344

$
2,172,390

$
1,526,882

$
3,699,272

Medical

877,773

27,055

904,828

1,842,900

54,965

1,897,865

Total health care distribution

2,005,380

809,792

2,815,172

4,015,290

1,581,847

5,597,137
Technology and value-added services

129,897

22,154

152,051

251,834

43,213

295,047

Total revenues
$
2,135,277

$
831,946

$
2,967,223

$
4,267,124

$
1,625,060

$
5,892,184

Three Months Ended

Six Months Ended

June 27, 2020

June 27, 2020

North America

International

Global

North America

International

Global
Revenues:

Health care distribution

Dental
$
515,946

$
425,346

$
941,292

$
1,404,318

$
1,012,050

$
2,416,368

Medical

596,588

21,222

617,810

1,374,616

43,882

1,418,498

Total health care distribution

1,112,534

446,568

1,559,102

2,778,934

1,055,932

3,834,866
Technology and value-added services

92,927

12,300

105,227

206,425

30,767

237,192
Total excluding Corporate TSA revenues ⁽¹⁾

1,205,461

458,868

1,664,329

2,985,359

1,086,699

4,072,058
Corporate TSA revenues ⁽¹⁾

0

20,070

20,070

0

41,212

41,212

Total revenues
$
1,205,461

$
478,938

$
1,684,399

$
2,985,359

$
1,127,911

$
4,113,270

geographic

~~(1)Corporate TSA revenues represents sales of certain animal~~area:

Three Months Ended

March 26, 2022

North America

International

Global

Revenues:

Health care distribution

Dental

1,105

723

1,828

Medical

1,150

1,172

Total health ~~products to Covetrus under the transition~~care distribution

2,255

745

3,000

Technology

and value-added services ~~agreement entered into in connection with the Animal~~

156

179

Total revenues

2,411

768

3,179

Three Months Ended

March 27, 2021

North America

International

Global

Revenues:

Health ~~Spin-off, which ended in December 2020. See~~ ~~Note-18 Related Party Transactions~~ ~~for further information.~~

care distribution

Dental

1,045

744

1,789

Medical

963

991

Total health care distribution

2,008

772

2,780

Technology

and value-added services

124

145

Total revenues

2,132

793

2,925

At December ~~26, 2020,~~25, 2021, the current portion of contract liabilities of ~~$71.5~~ $

million was reported in Accrued expenses:

Other, and ~~$8.2~~ $

million related to non-current contract liabilities was reported

in Other liabilities.

During the ~~six~~ three

months ended ~~June~~March 26, ~~2021,~~2022, we recognized in revenue ~~$47.1~~ $

million of the amounts that were previously deferred

at December 25, 2021.

At March 26, ~~2020. At June 26, 2021,~~2022, the current and non-current portion of contract liabilities

were ~~$70.9~~ $

million and ~~$9.0~~ $

million, respectively.

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in ~~thousands,~~millions, except share and per share data)

~~(unaudited~~)

(unaudited

)

Note 4

–

Segment Data

We conduct our business through

reportable segments: (i) health care distribution and (ii) technology

and

value-added services. These segments offer different products and services to the same customer

base.

The health care distribution reportable segment aggregates our global dental and medical operating segments. This segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. Our global

dental ~~group serves~~businesses serve office-based dental practitioners, dental laboratories, schools and

other institutions. Our

global medical ~~group serves~~businesses serve office-based medical practitioners, ambulatory

surgery centers, other alternate-care

settings and other institutions. Our global dental and medical groups serve

practitioners in

countries worldwide.

The health care distribution reportable segment aggregates our global

dental and medical operating segments. This

segment distributes consumable products, dental specialty products,

small equipment, laboratory products, large

equipment, equipment repair services, branded and generic pharmaceuticals,

vaccines, surgical products, diagnostic

tests, infection-control products, personal protective equipment (“PPE”)

and vitamins.

Our global technology and value-added services ~~group~~reportable segment provides

software, technology and other ~~value-added~~value-

added services to health care practitioners. Our technology ~~group~~ offerings include practice management

software systems

for dental and medical practitioners. Our value-added practice solutions

include practice consultancy, education,

revenue cycle management and financial services on a non-recourse basis,

e-services, practice technology, network

and hardware services, as well as continuing education services for practitioners.

The following tables present information about our reportable and operating

segments:

Three Months Ended

Six Months Ended

June 26,

June 27,

June 26,

June 27,

2021

2020

2021

2020
Net Sales:

Health care distribution ⁽¹⁾

Dental

$
1,910,344

$
941,292

$
3,699,272

$
2,416,368

Medical

904,828

617,810

1,897,865

1,418,498

Total health care distribution

2,815,172

1,559,102

5,597,137

3,834,866

Technology and value-added services ⁽²⁾

152,051

105,227

295,047

237,192

Total excluding Corporate TSA revenue

2,967,223

1,664,329

5,892,184

4,072,058

Corporate TSA revenues ⁽³⁾

0

20,070

0

41,212

Total

$
2,967,223

$
1,684,399

$
5,892,184

$
4,113,270

Three Months Ended

March 26,

March 27,

2022

2021

Net Sales:

Health care distribution

(1)

Dental

1,828

1,789

Medical

1,172

991

Total health care distribution

3,000

2,780

Technology

and value-added services

(2)

179

145

Total

3,179

2,925

(1)

Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and

generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic

products), diagnostic tests, infection-control products, ~~personal protective equipment~~PPE and vitamins.

(2)

Consists of practice management software and other value-added products, which are distributed primarily to health care providers,

practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing

education services for practitioners, consulting and other services.

~~(3)Corporate TSA revenues represents sales~~

Three Months Ended

March 26,

March 27,

2022

2021

Operating Income:

Health care distribution

211

197

Technology

and value-added services

Total

244

230

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in millions, except share and per share data)

(unaudited

)

Note 5

–

Business Acquisitions

2022 Acquisitions

During the three months ended March 26, 2022,

we made an acquisition within the technology and value-added

services segment.

The impact of this acquisition was not considered material to our

condensed consolidated

financial statements.

2021 Acquisitions

We completed acquisitions during the three months ended March 27, 2021 which were immaterial to our financial

statements.

Our ownership interest acquired ranges between approximately

% to

100

Acquisitions within our

health care distribution segment included

companies that specialize in distribution of dental products, a provider

home medical supplies, and product kitting and sterile packaging.

Within our technology and value-added services

segment, we acquired companies that focus on dental marketing and website

solutions, practice transition services,

and business analytics and intelligence software.

The following table aggregates the estimated fair value, as of the

date of acquisition, of consideration paid and net

assets acquired for acquisitions during the three months ended March 27, 2021.

While we use our best estimates

and assumptions to accurately value those assets acquired and liabilities

assumed at the acquisition date as well as

contingent consideration, where applicable, our estimates are inherently uncertain

and subject to refinement.

As a

result, during the measurement period we may record adjustments

to the assets acquired and liabilities assumed

with the corresponding offset to goodwill within our consolidated balance sheets.

Acquisition consideration:

Cash

212

Deferred consideration

Redeemable noncontrolling interests

Total consideration

289

Identifiable assets acquired and liabilities assumed:

Current assets

Intangible assets

151

Other noncurrent assets

Current liabilities

(32)

Deferred income taxes

(9)

Other noncurrent liabilities

(22)

Total identifiable

net assets

194

Goodwill

Total net assets acquired

289

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in millions, except share and per share data)

(unaudited

)

The following table summarizes the identifiable intangible assets acquired

during the quarter ended March 27, 2021

and their estimated useful lives as of the date of the acquisition:

Estimated

Useful Lives

(in years)

Trademark / Tradename

Non-compete agreements

Customer relationships and lists

120

Product development

Total

151

The major classes of assets and liabilities that we generally allocate purchase

price to, excluding goodwill, include

identifiable intangible assets (i.e., customer relationships and lists, trademarks

and trade names, product

development and non-compete agreements), inventory and accounts

receivable, property, plant and equipment,

deferred taxes and other current and long-term assets and liabilities.

The estimated fair value of identifiable

intangible assets is based on critical estimates, judgments and assumptions

derived from analysis of market

conditions, discount rates, discounted cash flows, customer retention rates

and estimated useful lives.

Some prior owners of acquired subsidiaries are eligible to receive additional

purchase price cash consideration if

certain ~~products~~financial targets are met.

We have accrued liabilities for the estimated fair value of additional purchase

price consideration at the time of the acquisition.

Any adjustments to ~~Covetrus~~these accrual amounts are recorded in our

consolidated statements of income.

For the three months ended March 26, 2022 and March 27, 2021, there were

material adjustments recorded in our consolidated statements of income

relating to changes in estimated contingent

purchase price liabilities.

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in millions, except share and per share data)

(unaudited

)

Note 6 – Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or

paid to transfer a liability in an orderly

transaction between market participants at the measurement date.

The fair value hierarchy distinguishes between

(1) market participant assumptions developed based on market data obtained

from independent sources (observable

inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best

information available in the circumstances (unobservable inputs).

The fair value hierarchy consists of three broad levels, which gives the

highest priority to unadjusted quoted prices

in active markets for identical assets or liabilities (Level 1) and the lowest priority

to unobservable inputs (Level 3).

The three levels of the fair value hierarchy are described as follows:

•

Level 1— Unadjusted quoted prices in active markets for identical assets

or liabilities that are accessible at the

measurement date.

•

Level 2— Inputs other than quoted prices included within Level 1 that are observable

for the asset or liability,

either directly or indirectly.

Level 2 inputs include: quoted prices for similar assets or liabilities

in active markets;

quoted prices for identical or similar assets or liabilities in markets that are

not active; inputs other than quoted

prices that are observable for the asset or liability; and inputs that are

derived principally from or corroborated by

observable market data by correlation or other means.

•

Level 3— Inputs that are unobservable for the asset or liability.

The following section describes the fair values of our financial instruments

and the methodologies that we used to

measure their fair values.

Investments and notes receivable

There are no quoted market prices available for investments in unconsolidated

affiliates and notes receivable;

however, we believe the carrying amounts are a reasonable estimate of fair value based on the interest

rates in the

applicable markets.

Debt

The fair value of our debt (including bank credit lines) is classified as

Level 3 within the fair value hierarchy, and

as of March 26, 2022 and December 25, 2021 was estimated at $

866

million and $

873

million, respectively.

Factors that we considered when estimating the fair value of our debt

included market conditions, such as interest

rates and credit spreads.

Derivative contracts

Derivative contracts are valued using quoted market prices and

significant other observable inputs.

We use

derivative instruments to minimize our exposure to fluctuations in foreign

currency exchange rates.

Our derivative

instruments primarily include foreign currency forward agreements related

to certain intercompany loans, certain

forecasted inventory purchase commitments with foreign suppliers,

foreign currency forward contracts to hedge a

portion of our euro-denominated foreign operations which are designated

as net investment hedges and a total

return swap for the purpose of economically hedging our unfunded

non-qualified supplemental executive retirement

plan and our deferred compensation plan.

The fair values for the majority of our foreign currency derivative contracts

are obtained by comparing our contract

rate to a published forward price of the underlying market rates, which

is based on market rates for comparable

transactions and are classified within Level 2 of the fair value hierarchy.

Note 11–Redeemable Noncontrolling

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in millions, except share and per share data)

(unaudited

)

Redeemable noncontrolling interests

The values for Redeemable noncontrolling interests are classified within

Level 3 of the fair value hierarchy and are

based on recent transactions and/or implied multiples of earnings.

See

Interests

for additional information.

The following table presents our assets and liabilities that are measured and

recognized at fair value on a recurring

basis classified under the ~~transition services agreement entered into in connection with~~appropriate level of the ~~Animal Health Spin-off, which ended in~~fair value hierarchy as of

March 26, 2022 and December ~~2020.~~ ~~See~~ ~~Note-18 Related Party Transactions~~ ~~for further information.~~

Three Months Ended

Six Months Ended

June 26,

June 27,

June 26,

June 27,

2021

2020

2021

2020
Operating Income (Loss):

Health care distribution

$
181,761

$
(25,348)

$
379,693

$
122,819

Technology and value-added services

28,585

17,915

60,581

43,613

Total

$
210,346

$
(7,433)

$
440,274

$
166,432
25,

2021:

March 26, 2022

Level 1

Level 2

Level 3

Total

Assets:

Derivative contracts designated as hedges

Derivative contracts undesignated

Total return

swaps

Total assets

Liabilities:

Derivative contracts designated as hedges

Derivative contracts undesignated

Total liabilities

Redeemable noncontrolling interests

613

December 25, 2021

Level 1

Level 2

Level 3

Total

Assets:

Derivative contracts designated as hedges

Derivative contracts undesignated

Total return

swaps

Total assets

Liabilities:

Derivative contracts designated as hedges

Derivative contracts undesignated

Total liabilities

Redeemable noncontrolling interests

613

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in ~~thousands,~~millions, except share and per share data)

~~(unaudited~~)

(unaudited

)

Note 57 – Debt

Bank Credit Lines

Bank credit lines consisted of the following:

June 26,

December 26,

2021

2020
Revolving credit agreement

$
0

$
0
Other short-term bank credit lines

72,105

73,366
Total

$
72,105

$
73,366

March 26,

December 25,

2022

2021

Revolving credit agreement

Other short-term bank credit lines

Total

Revolving Credit Agreement

On ~~April 18, 2017,~~

August 20, 2021

, we entered into a ~~$750 million~~new $

billion revolving credit agreement (the “Credit Agreement”),.

This

facility, which matures on

August 20, 2026

, replaced our $

750

million revolving credit facility, which was

scheduled to mature in April ~~2022~~. 2022.

The interest rate is based on the USD LIBOR plus a spread based on our

leverage ratio at the end of each financial reporting quarter. ~~We expect most~~

Most LIBOR rates ~~to be~~have been discontinued ~~immediately~~ after

December 31, 2021, while the remaining LIBOR rates will be discontinued

immediately after June 30, ~~2023, which will require an amendment to our debt agreements to reflect a new reference rate.~~ 2023.

do not expect the discontinuation of LIBOR as a reference rate in our

debt agreements to have a material adverse

effect on our financial position or to materially affect our interest expense.

The Credit Agreement also requires,

among other things, that we maintain certain maximum leverage ratios.

Additionally, the Credit Agreement

contains customary representations, warranties and affirmative covenants as well

as customary negative covenants,

subject to negotiated exceptions, on liens, indebtedness, significant corporate

changes (including mergers),

dispositions and certain restrictive agreements.

As of ~~June~~March 26, ~~2021,~~2022 and December ~~26, 2020,~~25, 2021, we had no

borrowings under this revolving credit facility.

As of ~~June~~March 26, ~~2021,~~2022 and December ~~26, 2020,~~25, 2021, there were $~~9.3~~

million and ~~$9.5~~ $

million of letters of credit, respectively, provided to third parties under the credit facility.

On April 17, 2020, we amended the Credit Agreement to, among other things, (i) modify the financial covenant from being based on total leverage ratio to net leverage ratio, (ii) adjust the pricing grid to reflect the net leverage ratio calculation, and (iii) increase the maximum maintenance leverage ratio through March 31, 2021.

~~364-Day Credit Agreement~~

On March 4, 2021, we repaid the outstanding obligations and terminated the lender commitments under our $700 million 364-day credit agreement which was entered into on April 17, 2020. This facility was originally scheduled to mature on April 16, 2021.

Other Short-Term Bank Credit

Lines

As of ~~June~~March 26, ~~2021~~2022 and December ~~26, 2020,~~25, 2021, we had various other short-term

bank credit lines available, of

which ~~$72.1~~ $

million and ~~$73.4~~ $

million, respectively, were outstanding.

At ~~June~~March 26, ~~2021~~2022 and December ~~26, 2020,~~ 25, 2021,

borrowings under all of these credit lines had a weighted average interest

rate of ~~5.98%~~

8.91

% and ~~4.14%~~

10.44

%, respectively.

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in ~~thousands,~~millions, except share and per share data)

~~(unaudited~~)

(unaudited

)

Long-term debt

Long-term debt consisted of the following:

June 26,

December 26,

2021

2020
Private placement facilities

$
706,332

$
613,498
Note payable

0

1,554
Various collateralized and uncollateralized loans payable with interest,

in varying installments through 2023 at interest rates

ranging from 2.45% to 4.27% at June 26, 2021 and

ranging from 2.62% to 4.27% at December 26, 2020

4,293

4,596
Finance lease obligations (see Note 6)

5,701

5,961

Total

716,326

625,609
Less current maturities

(9,839)

(109,836)

Total long-term debt

$
706,487

$
515,773

March 26,

December 25,

2022

2021

Private placement facilities

699

706

U.S. trade accounts receivable securitization

105

Various

collateralized and uncollateralized loans payable with interest,

in varying installments through 2023 at interest rates

ranging from

% to

4.27

% at March 26, 2022 and

ranging from

2.62

% to

4.27

% at December 25, 2021

Finance lease obligations

Total

776

822

Less current maturities

(3)

(11)

Total long-term debt

773

811

Private Placement Facilities

Our private placement facilities ~~with~~ were amended on

October 20, 2021

to include

(previously

) insurance

companies, have a total facility amount of $1 $

1.5

billion (previously $

1.0

billion), and are available on an

uncommitted basis at fixed rate economic terms to be agreed upon at

the time of issuance, from time to time

through

October 20, 2026

(previously

June 23, ~~2023.~~ 2023

The facilities allow us to issue senior promissory notes to

the lenders at a fixed rate based on an agreed upon spread over applicable

treasury notes at the time of

issuance.

The term of each possible issuance will be selected by us and

can range from

five

15 years ~~(with~~

(with an

average life no longer than

12 ~~years)~~years

The proceeds of any issuances under the facilities will be used for

general

corporate purposes, including working capital and capital expenditures,

to refinance existing indebtedness, and/or

to fund potential acquisitions.

The agreements provide, among other things, that we maintain

certain maximum

leverage ratios, and contain restrictions relating to subsidiary indebtedness,

liens, affiliate transactions, disposal of

assets and certain changes in ownership.

These facilities contain make-whole provisions in the event that we

pay

off the facilities prior to the applicable due dates.

On March 5, 2021, we amended the private placement facilities to, among other things, (a) modify the financial covenant from being based on a net leverage ratio to a total leverage ratio and (b) restore the maximum maintenance total leverage ratio to 3.25x and remove the 1.00% interest rate increase triggered if the net leverage ratio were to exceed 3.0x.

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

The components of our private placement facility borrowings as

of ~~June~~March 26, ~~2021~~2022 are presented in the following ~~table (in thousands):~~

Amount of

Borrowing

Borrowing

Date of Borrowing

Outstanding

Rate

Due Date
January 20, 2012 (1)

$
7,143

3.09
%

January 20, 2022
January 20, 2012

50,000

3.45

January 20, 2024
December 24, 2012

50,000

3.00

December 24, 2024
June 16, 2017

100,000

3.42

June 16, 2027
September 15, 2017

100,000

3.52

September 15, 2029
January 2, 2018

100,000

3.32

January 2, 2028
September 2, 2020

100,000

2.35

September 2, 2030
June 2, 2021

100,000

2.48

June 2, 2031
June 2, 2021

100,000

2.58

June 2, 2033
Less: Deferred debt issuance costs

(811)

$
706,332

(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.

table:

Amount of

Borrowing

Date of Borrowing

Outstanding

Rate

Due Date

January 20, 2012

3.45

January 20, 2024

December 24, 2012

3.00

December 24, 2024

June 16, 2017

100

3.42

June 16, 2027

September 15, 2017

100

3.52

September 15, 2029

January 2, 2018

100

3.32

January 2, 2028

September 2, 2020

100

2.35

September 2, 2030

June 2, 2021

100

2.48

June 2, 2031

June 2, 2021

100

2.58

June 2, 2033

Less: Deferred debt issuance costs

(1)

Total

699

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in millions, except share and per share data)

(unaudited

)

U.S. Trade Accounts Receivable Securitization

We have a facility agreement ~~with a bank, as agent,~~ based on the securitization of our U.S. trade accounts receivable that is structured as

an asset-backed securitization program with pricing committed for up

three ~~years.~~ years

Our current facility, which ~~has~~

had a purchase limit of ~~$350~~ $

350

million, was scheduled to expire on

April 29, ~~2022.~~ 2022

On ~~June 22, 2020,~~October 20, 2021, we

amended our U.S. trade accounts receivable securitization facility to

increase the purchase limit to $

450

million

with

banks as agents and extend the expiration date ~~for this facility was extended~~ to ~~June 12, 2023 and was amended to adjust certain covenant levels for 2020.~~

October 18, 2024

As of ~~June~~March 26, ~~2021~~2022 and December ~~26, 2020, there were 0~~

25, 2021, the borrowings outstanding under this securitization ~~facility.~~ facility were

million and $

105

million,

respectively.

At ~~June~~March 26, 2022, the interest rate on borrowings under

this facility was based on the asset-backed

commercial paper rate of

0.53

% plus

0.75

%, for a combined rate of

1.28

At December 25, 2021, the interest rate

on borrowings under this facility was based on the asset-backed commercial

paper rate of ~~0.14%~~

0.19

% plus ~~0.95%~~

0.75

%, for a

combined rate of ~~1.09%~~

0.94

%. ~~At December 26, 2020, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 0.22% plus 0.95%, for a combined rate of 1.17%.~~

If our accounts receivable collection pattern changes due to customers

either paying late or not making payments,

our ability to borrow under this facility may be reduced.

We are required to pay a commitment fee of 25

to 45

basis points depending upon program utilization.

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

Note 68 – ~~Leases~~

~~Leases~~

We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles, and certain equipment. Our leases have remaining terms of less than one year to approximately 15 years, some of which may include options to extend the leases for up to 10 years. The components of lease expense were as follows:

Three Months Ended

Six Months Ended

June 26,

June 27,

June 26,

June 27,

2021

2020

2021

2020

Operating lease cost:⁽¹⁾

$
25,840

$
21,991

$
48,946

$
44,070

Finance lease cost:

Amortization of right-of-use assets

516

282

1,120

714

Interest on lease liabilities

27

20

53

57

Total finance lease cost

$
543

$
302

$
1,173

$
771

(1)
Includes variable lease expenses.

Supplemental balance sheet information related to leases is as follows:

June 26,

December 26,

2021

2020

Operating Leases:

Operating lease right-of-use assets

$
301,440

$
288,847

Current operating lease liabilities

75,008

64,716

Non-current operating lease liabilities

243,232

238,727

Total operating lease liabilities

$
318,240

$
303,443

Finance Leases:

Property and equipment, at cost

$
11,443

$
10,683

Accumulated depreciation

(5,170)

(4,277)

Property and equipment, net of accumulated depreciation

$
6,273

$
6,406

Current maturities of long-term debt

$
2,420

$
2,420

Long-term debt

3,281

3,541

Total finance lease liabilities

$
5,701

$
5,961

Weighted Average Remaining Lease Term in Years:

Operating leases

7.1

7.5

Finance leases

4.0

4.3

Weighted Average Discount Rate:

Operating leases

2.6
%

2.8
%

Finance leases

1.8
%

1.9
%
Income Taxes

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

Supplemental cash flow information related to leases is as follows:

Six Months Ended

June 26,

June 27,

2021

2020

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows for operating leases

$
39,988

$
38,579

Operating cash flows for finance leases

47

50

Financing cash flows for finance leases

1,407

947

Right-of-use assets obtained in exchange for lease obligations:

Operating leases

$
49,226

$
14,926

Finance leases

1,244

1,814

Maturities of lease liabilities are as follows:

June 26, 2021

Operating

Finance

Leases

Leases

2021

$
42,284

$
1,384

2022

72,260

1,930

2023

49,569

963

2024

35,148

393

2025

30,519

337

Thereafter

118,761

895

Total future lease payments

348,541

5,902

Less: imputed interest

(30,301)

(201)

Total

$
318,240

$
5,701

As of June 26, 2021, we have additional operating leases with total lease payments of $12.5 million for buildings and vehicles that have not yet commenced. These operating leases will commence subsequent to June 26, 2021, with lease terms of two years to 10 years.

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

For the three months ended March 26, 2022 our effective tax rate was

24.0

% compared to

~~Note 7 – Redeemable Noncontrolling Interests~~

~~Some minority stockholders in certain~~

25.1

% for the prior year

period.

The difference between our effective tax rates and the federal statutory tax rate for

the three months ended

March 26, 2022 primarily relates to state and foreign income taxes and

interest expense as well as share-based

compensation.

The difference between our effective tax rate and the federal statutory tax rate for the three

months

ended March 27, 2021 was primarily due to state and foreign income

taxes and interest expense.

The total amount of unrecognized tax benefits, which are included in

“other liabilities” within our ~~subsidiaries have~~consolidated

balance sheets, as of March 26, 2022 and December 25, 2021 was $

million and $

million, respectively of

which $

million and $

million, respectively, would affect the ~~right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Accounting Standards Codification (“ASC”) Topic 480-10~~effective tax rate if recognized.

It is ~~applicable for noncontrolling interests where we are or may be required to purchase all or a portion~~possible that

the amount of ~~the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the~~unrecognized tax benefits will change in the ~~redeemable noncontrolling interests~~next 12

months, which may result in a material impact

on our consolidated statements of income.

All tax returns audited by the IRS are officially closed through 2016.

The tax years subject to examination by the

IRS include years 2017 and forward.

During the quarter ended December 25, 2021, we were notified

by the IRS

that tax year 2019 was selected for examination.

During the quarter ended September 26, 2020 we reached an agreement

with the Advanced Pricing Division on an

appropriate transfer pricing methodology for the ~~six~~years 2014-2025.

The objective of this resolution was to mitigate

future transfer pricing audit adjustments.

The total amounts of interest and penalties are classified as a component

of the provision for income taxes.

The

amount of tax interest expense was $

million for each of the three months ended ~~June~~March 26, ~~2021~~2022 and March

27,

2021.

The total amount of accrued interest is included in “Other liabilities,”

and was $

million as of March 26,

2022 and $

million as of December 25, 2021.

NaN

penalties were accrued for the ~~year ended December 26, 2020 are presented~~ periods presented.

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in ~~the following table:~~

June 26,

December 26,

2021

2020
Balance, beginning of period

$
327,699

$
287,258
Decrease in redeemable noncontrolling interests due to

redemptions

(1,130)

(17,241)
Increase in redeemable noncontrolling interests due to business

acquisitions

140,155

28,387
Net income attributable to redeemable noncontrolling interests

14,033

13,363
Dividends declared

(9,954)

(12,631)
Effect of foreign currency translation gain (loss) attributable to

redeemable noncontrolling interests

570

(4,279)
Change in fair value of redeemable securities

132,708

32,842
Balance, end of period

$
604,081

$
327,699

millions, except share and per share data)

(unaudited

)

Note 89 – ~~Comprehensive Income~~

~~Comprehensive~~ Legal Proceedings

Henry Schein has been named as a defendant in multiple lawsuits (currently

less than one-hundred and seventy-five

(

175

); in less than half of those cases one or more of Schein’s affiliated companies is also named as a defendant),

which

lawsuits allege that manufacturers of prescription opioid drugs engaged in a false advertising campaign to

expand the market for such drugs and their own market share and that the entities in the supply chain (including

Henry Schein, Inc.) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict

the improper distribution of those drugs

. These actions consist of some that have been consolidated

within the

MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription

Opiate Litigation (MDL No. 2804; Case

No. 17-md-2804) and are currently abated for discovery purposes, and others

which remain pending in state courts

and are proceeding independently and outside of the MDL.

At this time, the only cases set for trial are: the action

filed by Mobile County Board of Health, et al., in Alabama state court, which

is currently set for a jury trial on

January 9, 2023; and the action filed by DCH Health Care Authority, et al. in Alabama state court, which is

currently scheduled for a jury trial on March 20, 2023.

The court for the pending cases filed by hospitals in West

Virginia has indicated that it intends to set trials for all defendants in 2022.

However, as of this filing, the West

Virginia hospital cases against Henry Schein have not been set for trial.

Of Henry Schein’s 2021 sales of

approximately $

12.4

billion, sales of opioids represented less than two-tenths of

percent.

Opioids represent a

negligible part of our business.

We intend to defend ourselves vigorously against these actions.

From time to time, we may become a party to other legal proceedings,

including, without limitation, product

liability claims, employment matters, commercial disputes, governmental

inquiries and investigations (which may

in some cases involve our entering into settlement arrangements or consent

decrees), and other matters arising out

of the ordinary course of our business.

While the results of any legal proceeding cannot be predicted with certainty,

in our opinion none of these other pending matters are currently anticipated

to have a material adverse effect on our

consolidated financial position, liquidity or results of operations.

As of March 26, 2022, we had accrued our best estimate of potential losses

relating to claims that were probable to

result in liability and for which we were able to reasonably estimate a

loss.

This accrued amount, as well as related

expenses, was not material to our financial position, results of operations

or cash flows.

Our method for

determining estimated losses considers currently available facts, presently

enacted laws and regulations and other

factors, including probable recoveries from third parties.

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in millions, except share and per share data)

(unaudited

)

Note 10 – Stock-Based Compensation

Stock-based awards are provided to certain employees under the terms of

our 2020 Stock Incentive Plan and to

non-employee directors under the terms of our 2015 Non-Employee Director

Stock Incentive Plan (together, the

“Plans”).

The Plans are administered by the Compensation Committee of the Board

of Directors (the

“Compensation Committee”).

Historically, equity-based awards to our employees have been granted solely in the

form of time-based and performance-based restricted stock units (“RSUs”).

However, for our 2021 fiscal year, in

light of the COVID-19 pandemic, the Compensation Committee determined

it would be difficult for management

to set a meaningful three-year cumulative earnings per share target as the goal applicable

to performance-based

restricted stock unit awards as it had done in prior years.

Instead, the Compensation Committee set our equity-

based awards to employees for fiscal 2021 in the form of time-based RSUs

and non-qualified stock options which

focus on stock value appreciation and retention instead of pre-established

performance goals.

Our non-employee

directors continued to receive equity-based wards for fiscal 2021 solely in

the form of time-based RSUs.

During

the three months ended March 26, 2022, the Compensation Committee

reinstated performance-based RSUs for

equity-based awards to employees for fiscal 2022 and awarded grants in

the form of time-based RSUs,

performance-based RSUs and non-qualified stock options.

RSUs are stock-based awards granted to recipients with specified vesting provisions.

In the case of RSUs, common

stock is generally delivered on or following satisfaction of vesting conditions.

We issue RSUs to employees that

vest (i) solely based on the recipient’s continued service over time, primarily with

four

-year cliff vesting and/or (ii)

based on achieving specified performance measurements and the recipient’s continued service over time, primarily

with

three

-year cliff vesting.

RSUs granted under the 2015 Non-Employee Director Stock Incentive

Plan primarily

are granted with

-month cliff vesting.

For these RSUs, we recognize the cost as compensation expense on

straight-line basis.

With respect to time-based RSUs, we estimate the fair value on the date of grant based on our closing

stock price at

the time of grant.

With respect to performance-based RSUs, the number of shares that ultimately vest and

are

received by the recipient is based upon our performance as measured against

specified targets over a specified

period, as determined by the Compensation Committee.

Although there is no guarantee that performance targets

will be achieved, we estimate the fair value of performance-based RSUs

based on our closing stock price at time of

grant.

Each of the Plans provide for certain adjustments to awards under

the Plans and with respect to the performance

goals under the performance-based RSUs granted under our 2020 Stock

Incentive Plan, including adjustment to the

goals for significant events, including, without limitation, acquisitions,

divestitures, new business ventures, certain

capital transactions (including share repurchases), other differences in budgeted average

outstanding shares (other

than those resulting from capital transactions referred to above), restructuring

costs, if any, certain litigation

settlements or payments, if any, changes in accounting principles or in applicable laws or regulations, changes in

income ~~includes~~tax rates in certain ~~gains~~markets, foreign exchange fluctuations, and ~~losses~~

unforeseen events or circumstances

affecting the Company.

Over the performance period, the number of shares of common stock

that will ultimately

vest and be issued and the related compensation expense is adjusted upward

or downward based upon our

estimation of achieving such performance targets.

The ultimate number of shares delivered to recipients

and the

related compensation cost recognized as an expense will be based on our

actual performance metrics as defined

under ~~U.S. GAAP,~~the Plans.

Stock options are ~~excluded~~ awards that allow the recipient to purchase shares of our

common stock at a fixed price following

vesting of the stock options.

Stock options are granted at an exercise price equal to our closing stock price

on the

date of grant.

Stock options issued beginning in 2021 vest

one-third

per year based on the recipient’s continued

service, subject to the terms and conditions of the 2020 Stock Incentive Plan,

are fully vested

three years

from ~~net income as~~the

grant date and have a contractual term of

ten years

from the grant date, subject to earlier termination of the term

upon certain events.

Compensation expense for these stock options is recognized

using a graded vesting method.

We estimate the fair value of stock options using the Black-Scholes valuation model.

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in millions, except share and per share data)

(unaudited

)

In addition to equity-based awards granted in fiscal 2021 under the Company’s long-term incentive program, the

Compensation Committee granted a Special Pandemic Recognition Award under the 2020 Stock Incentive Plan to

recipients of performance-based RSUs under the 2018 long-term

incentive program.

The payout under the

performance-based restricted stock units granted under the fiscal 2018

long-term incentive program (the “2018

LTIP”) was negatively impacted by the global COVID-19 pandemic.

Given the significance of the impact of the

pandemic on the Company’s

three-year

EPS goal under such ~~amounts~~equity awards and the contributions made

by the

Company’s employees (including those who received such awards), on March 3, 2021, the Compensation

Committee granted a Special Pandemic Recognition Award to recipients of performance-based restricted stock

units under the 2018 LTIP who were employed by the Company on the grant date of the Special Pandemic

Recognition Award.

These time-based RSU awards vest

% on the first anniversary of the grant date and

% on

the second anniversary of the grant date, based on the recipient’s continued service and subject to the terms

and

conditions of the 2020 Stock Incentive Plan, and are recorded ~~directly~~ as compensation

expense using a graded vesting

method.

The combination of the

% payout based on actual performance of the 2018 LTIP and the one-time

Special Pandemic Recognition Award granted in 2021 will generate a cumulative payout of

% of each recipient’s

original number of performance-based restricted stock units awarded in 2018

if the recipient satisfies the

two-year

vesting schedule commencing on the grant date.

Our accompanying condensed consolidated statements of income reflect

pre-tax share-based compensation expense

of $

million ($

million after-tax) and $

million ($

million after-tax) for the three months ended March 26,

2022 and March 27, 2021, respectively.

Total unrecognized compensation cost related to unvested awards as of March 26, 2022 was $

134

million, which is

expected to be recognized over a weighted-average period of approximately

2.6

years.

Our accompanying condensed consolidated statements of cash flows present

our stock-based compensation expense

as an adjustment to ~~stockholders’ equity.~~

reconcile net income to net cash provided by operating

activities for all periods presented.

the accompanying consolidated statements of cash flows, there were

benefits associated with tax deductions in

excess of recognized compensation as a cash inflow from financing

activities for the three months ended March 26,

2022 and March 27, 2021, respectively.

The following weighted-average assumptions were used in determining

the most recent fair values of stock options

granted using the Black-Scholes valuation model:

2022

Expected dividend yield

0.0

Expected stock price volatility

27.20

Risk-free interest rate

2.20

Expected life of options (years)

6.00

We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in

the foreseeable future.

The expected stock price volatility is based on implied volatilities

from traded options on

our stock, historical volatility of our stock, and other factors.

The risk-free interest rate is based on the U.S.

Treasury yield curve in effect at the time of grant in conjunction with considering the expected life of options.

The

six-year expected life of the options was determined using the simplified

method for estimating the expected term

as permitted under SAB Topic 14.

Estimates of fair value are not intended to predict actual future events or

the

value ultimately realized by recipients of stock options, and subsequent

events are not indicative of the

reasonableness of the original estimates of fair value made by us.

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in millions, except share and per share data)

(unaudited

)

The following table summarizes ~~our Accumulated other comprehensive loss, net of applicable taxes as of:~~

June 26,

December 26,

2021

2020
Attributable to Redeemable noncontrolling interests:

Foreign currency translation adjustment

$
(24,047)

$
(24,617)

Attributable to noncontrolling interests:

Foreign currency translation adjustment

$
466

$
235

Attributable to Henry Schein, Inc.:

Foreign currency translation adjustment

$
(77,709)

$
(76,565)

Unrealized loss from foreign currency hedging activities

(9,878)

(11,488)

Unrealized investment gain (loss)

(2)

1

Pension adjustment loss

(19,190)

(20,032)

Accumulated other comprehensive loss

$
(106,779)

$
(108,084)

Total Accumulated other comprehensive loss

$
(130,360)

$
(132,466)

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

~~The following table summarizes~~stock option activity under the ~~components of comprehensive income, net of applicable taxes as follows:~~

Three Months Ended

Six Months Ended

June 26,

June 27,

June 26,

June 27,

2021

2020

2021

2020
Net income (loss)

$
163,977

$
(13,267)

$
338,905

$
120,298

Foreign currency translation gain (loss)

38,138

34,408

(343)

(54,904)
Tax effect

0

0

0

0
Foreign currency translation gain (loss)

38,138

34,408

(343)

(54,904)

Unrealized gain (loss) from foreign currency hedging

activities

(2,438)

(6,733)

2,257

13,500
Tax effect

687

1,744

(647)

(3,346)
Unrealized gain (loss) from foreign currency hedging

activities

(1,751)

(4,989)

1,610

10,154

Unrealized investment gain (loss)

4

3

(4)

(8)
Tax effect

(1)

(1)

1

1
Unrealized investment gain (loss)

3

2

(3)

(7)

Pension adjustment gain (loss)

(3)

(350)

1,023

698
Tax effect

38

125

(181)

(199)
Pension adjustment gain (loss)

35

(225)

842

499
Comprehensive income

$
200,402

$
15,929

$
341,011

$
76,040

Plans

~~The change in the unrealized gain (loss) from foreign currency hedging activities~~ during the three months ~~and year~~ ended ~~June~~March 26, ~~2021, compared~~

2022:

Stock Options

Weighted

Average

Weighted

Remaining

Average

Contractual

Aggregate

Exercise

Life in

Intrinsic

Price

Years

Value

Outstanding at beginning of period

767,717

63.24

Granted

396,874

86.27

Exercised

(26,233)

62.71

Forfeited

(1,688)

62.71

Outstanding at end of period

1,136,670

71.30

9.3

Options exercisable at end of period

220,065

62.71

Weighted

Average

Remaining

Aggregate

Number of

Exercise

Contractual

Intrinsic

Options

Price

Life (in years)

Value

Vested

or expected to vest

891,140

73.66

9.4

The following tables summarize the ~~comparable prior year period, was primarily attributable to a net investment hedge that was entered into during 2019. See~~ ~~Note 14-Derivatives and Hedging Activities~~

activity of our unvested RSUs for ~~further information.~~

~~Our financial statements are denominated in~~

the U.S. Dollar currency. Fluctuations in the value of foreign currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income. The foreign currency translation gain (loss) during the sixthree months ended ~~June~~March 26, ~~2021 and six months ended June 27, 2020~~ ~~was primarily impacted by changes in foreign currency exchange rates~~ 2022:

Time-Based Restricted Stock Units

Weighted Average

Grant Date Fair

Intrinsic Value

Shares/Units

Value Per Share

Per Share

Outstanding at beginning of ~~the Euro, British Pound, Brazilian Real, Australian Dollar and Canadian Dollar.~~

period

~~The following table summarizes our total comprehensive income, net~~

1,945,862

58.79

Granted

427,978

86.43

Vested

(489,549)

54.57

Forfeited

(7,374)

61.18

Outstanding at end of ~~applicable taxes, as follows:~~

Three Months Ended

Six Months Ended

June 26,

June 27,

June 26,

June 27,

2021

2020

2021

2020
Comprehensive income attributable to

Henry Schein, Inc.

$
185,242

$
17,600

$
323,018

$
87,586
Comprehensive income (loss) attributable to

noncontrolling interests

1,437

(744)

3,390

(431)
Comprehensive income (loss) attributable to

Redeemable noncontrolling interests

13,723

(927)

14,603

(11,115)
Comprehensive income

$
200,402

$
15,929

$
341,011

$
76,040
period

1,876,917

66.30

87.85

Performance-Based Restricted Stock Units

Weighted Average

Grant Date Fair

Intrinsic Value

Shares/Units

Value Per Share

Per Share

Outstanding at beginning of period

674,753

59.63

Granted

460,896

70.93

Vested

(386,612)

59.08

Forfeited

(1,752)

60.56

Outstanding at end of period

747,285

56.77

87.85

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in ~~thousands,~~millions, except share and per share data)

~~(unaudited~~)

(unaudited

)

~~Note 9 – Fair Value Measurements~~

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).

The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described as follows:

~~• Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.~~

• Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

~~• Level 3— Inputs that are unobservable for the asset or liability.~~

~~The following section describes the fair values of our financial instruments and the methodologies that we used to measure their fair values.~~

~~Investments and notes receivable~~

There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable; however, we believe the carrying amounts are a reasonable estimate of fair value based on the interest rates in the applicable markets.

~~Debt~~

The fair value of our debt (including bank credit lines) is classified as Level 3 within the fair value hierarchy as of June 26, 2021 and December 26, 2020 was estimated at $788.4 million and $699.0 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, such as interest rates and credit spreads.

~~Derivative contracts~~

Derivative contracts are valued using quoted market prices and significant other observable and unobservable inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers, foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges and a total return swap for the purpose of economically hedging our unfunded non-qualified supplemental retirement plan and our deferred compensation plan.

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which is based on market rates for comparable transactions and are classified within Level 2 of the fair value hierarchy. See ~~Note 14-Derivatives and Hedging Activities~~

~~for further information.~~

~~Redeemable noncontrolling interests~~

~~The values for Redeemable noncontrolling interests are classified within Level 3 of the fair value hierarchy and are based on recent transactions and/or implied multiples of earnings. See~~ ~~Note 7–Redeemable Noncontrolling Interests~~

~~for additional information.~~

The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of June 26, 2021 and December 26, 2020:

June 26, 2021

Level 1

Level 2

Level 3

Total

Assets:

Derivative contracts

$
0

$
1,471

$
0

$
1,471

Total return swaps

0

1,317

0

1,317

Total assets

$
0

$
2,788

$
0

$
2,788

Liabilities:

Derivative contracts

$
0

$
9,542

$
0

$
9,542

Total liabilities

$
0

$
9,542

$
0

$
9,542

Redeemable noncontrolling interests

$
0

$
0

$
604,081

$
604,081

December 26, 2020

Level 1

Level 2

Level 3

Total

Assets:

Derivative contracts

$
0

$
1,868

$
0

$
1,868

Total return swaps

0

1,565

0

1,565

Total assets

$
0

$
3,433

$
0

$
3,433

Liabilities:

Derivative contracts

$
0

$
11,765

$
0

$
11,765

Total liabilities

$
0

$
11,765

$
0

$
11,765

Redeemable noncontrolling interests

$
0

$
0

$
327,699

$
327,699

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

~~Note 10~~ – ~~Business Acquisitions~~

~~Acquisitions~~

We completed acquisitions during the six months ended June 26, 2021 which were immaterial to our financial statements. The acquisitions that we completed included companies within our Health care distribution and Technology and value-added services segments. The initial ownership interest we acquired in these companies ranged from approximately 51% to 100%. Acquisitions within our Health care distribution segment included companies that specialize in the distribution of dental products, a provider of home medical supplies, and a provider of product kitting and sterile packaging. Within our Technology and value-added services segment, we acquired companies that focus on dental marketing and website solutions, practice transition services, and business analytics and intelligence software.

The following table summarizes the estimated fair value, as of the date of acquisition, of consideration paid and net assets acquired for acquisitions during the six months ended June 26, 2021. While we use our best estimates and assumptions to accurately value those assets acquired and liabilities assumed at the acquisition date as well as contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill within our consolidated balance sheets.

Acquisition consideration:

Cash
$
310,523
Redeemable noncontrolling interests

129,319
Total consideration

439,842

Identifiable assets acquired and liabilities assumed:

Current assets

107,197
Intangible assets

183,796
Other noncurrent assets

33,959
Current liabilities

(43,781)
Deferred income taxes

(17,442)
Other noncurrent liabilities

(37,462)
Total identifiable net assets

226,267
Goodwill

213,575
Total net assets acquired
$
439,842

The major classes of assets and liabilities that we generally allocate purchase price to, excluding goodwill, include identifiable intangible assets (i.e., trademarks and trade names, customer relationships and lists, non-compete agreements and product development), property, plant and equipment, deferred taxes and other current and long-term assets and liabilities. The estimated fair value of identifiable intangible assets is based on critical estimates, judgments and assumptions derived from analysis of market conditions, discount rates, discounted cash flows, customer retention rates and estimated useful lives.

Some prior owners of acquired subsidiaries are eligible to receive additional purchase price cash consideration if certain financial targets are met. We have accrued liabilities for the estimated fair value of additional purchase price consideration at the time of the acquisition. Any adjustments to these accrual amounts are recorded in our consolidated statements of income. For the six months ended June 26, 2021 and June 27, 2020, there were no material adjustments recorded in our consolidated statements of income relating to changes in estimated contingent purchase price liabilities.

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

Note 11 – ~~Plans~~Redeemable Noncontrolling Interests

Some minority stockholders in certain of ~~Restructuring~~

our subsidiaries have the right,

~~On November 20, 2019,~~at certain times, to require us to acquire

their ownership interest in those entities at fair value.

Accounting Standards Codification Topic 480-10 is

applicable for noncontrolling interests where we ~~committed~~ are or may be required

to purchase all or a ~~contemplated initiative, intended to mitigate stranded costs associated with~~portion of the ~~Animal Health Spin-off and to rationalize operations and to provide expense efficiencies. These activities were originally expected to be completed by~~

outstanding interest in a consolidated subsidiary from the ~~end~~noncontrolling

interest holder under the terms of ~~2020. In light~~a put

option contained in contractual agreements.

The components of the ~~changes to~~change in the ~~business environment brought on by the COVID-19 pandemic, we extended such activities to the end of 2021.~~

~~During~~redeemable noncontrolling

interests for the three months ended ~~June~~March 26, 2022 and the year ended December

25, 2021 are presented in the

following table:

March 26,

December 25,

2022

2021

Balance, beginning of period

613

328

Decrease in redeemable noncontrolling interests due to acquisitions of

noncontrolling interests in subsidiaries

(3)

(60)

Increase in redeemable noncontrolling interests due to business

acquisitions

189

Net income attributable to redeemable noncontrolling interests

Dividends declared

(5)

(21)

Effect of foreign currency translation gain (loss) attributable to

redeemable noncontrolling interests

(6)

Change in fair value of redeemable securities

160

Balance, end of period

613

Note 12 – Comprehensive Income

Comprehensive income includes certain gains and ~~June 27, 2020, we~~losses that, under U.S.

GAAP,

are excluded from net income as

such amounts are recorded restructuring costs of $0.6 million and $15.9 million. During the six months ended June 26, 2021 and June 27, 2020, we recorded restructuring costs of $3.5 million and $20.7 million. The restructuring costs for these periods included costs for severance benefits and facility exit costs. The costs associated with these restructurings are included in a separate line item, “Restructuring costs” within our consolidated statements of income.

~~We are currently unable in good faith~~directly as an adjustment to make a determination of an estimate of the amount or range of amounts expected to be incurred in connection with these activities in 2021, both with respect to each major type of cost associated therewith and with respect to the total cost, or an estimate of the amount or range of amounts that will result in future cash expenditures.

stockholders’

equity.

The following table ~~shows the~~summarizes our Accumulated other comprehensive loss, net ~~amounts expensed and paid for restructuring costs that were incurred during the six months ended June 26, 2021 and during our 2020 fiscal year and the remaining accrued balance~~ of ~~restructuring costs~~

applicable taxes as ~~of June 26, 2021, which is included in Accrued expenses: Other within our consolidated balance sheets:~~

Facility

Severance

Closing

Costs

Costs

Other

Total
Balance, December 28, 2019

$
12,911

$
826

$
73

$
13,810
Provision

25,855

5,878

360

32,093
Payments and other adjustments

(26,152)

(6,309)

(329)

(32,790)
Balance, December 26, 2020

$
12,614

$
395

$
104

$
13,113
Provision

3,436

(122)

221

3,535
Payments and other adjustments

(12,736)

50

(321)

(13,007)
Balance, June 26, 2021

$
3,314

$
323

$
4

$
3,641

of:

The following table shows, by reportable segment, the net amounts expensed and paid for restructuring costs that were incurred during the six months ended June 26, 2021 and during our 2020 fiscal year and the remaining accrued balance of restructuring costs as of June 26, 2021:

Technology and

Health Care

Value-Added

Distribution

Services

Total
Balance, December 28, 2019

$
13,373

$
437

$
13,810
Provision

30,935

1,158

32,093
Payments and other adjustments

(31,484)

(1,306)

(32,790)
Balance, December 26, 2020

$
12,824

$
289

$
13,113
Provision

3,082

453

3,535
Payments and other adjustments

(12,561)

(446)

(13,007)
Balance, June 26, 2021

$
3,345

$
296

$
3,641

Table of ~~common shares outstanding for the period. Our diluted earnings~~Contents

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

March 26,

December 25,

2022

~~Note 12~~ – ~~Earnings Per Share~~

~~Basic earnings per share is computed by dividing net income attributable~~

2021

Attributable to Redeemable noncontrolling interests:

Foreign currency translation adjustment

(30)

(31)

Attributable to Henry Schein, Inc. ~~by the weighted-average number~~:

Foreign currency translation adjustment

(153)

(155)

Unrealized loss from foreign currency hedging activities

(1)

(2)

Pension adjustment loss

(14)

Accumulated other comprehensive loss

(168)

(171)

Total Accumulated

other comprehensive loss

(198)

(202)

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in millions, except share and per share ~~is computed similarly~~data)

(unaudited

)

The following table summarizes the components of comprehensive income, net

of applicable taxes as follows:

Three Months Ended

March 26,

March 27,

2022

2021

Net income

186

175

Foreign currency translation gain (loss)

(38)

Tax effect

Foreign currency translation gain (loss)

(38)

Unrealized gain from foreign currency hedging activities

Tax effect

(1)

Unrealized gain from foreign currency hedging activities

Pension adjustment gain

Tax effect

Pension adjustment gain

Comprehensive income

190

141

Our financial statements are denominated in the U.S. Dollar currency.

Fluctuations in the value of foreign

currencies as compared to ~~basic earnings per share, except that it reflects~~ the ~~effect of common shares issuable for presently unvested restricted stock and restricted stock units and upon exercise of stock options using the treasury stock method in periods in which they~~U.S. Dollar may have a ~~dilutive effect.~~

~~A reconciliation of shares used in calculating earnings per basic and diluted share follows:~~

Three Months Ended

Six Months Ended

June 26,

June 27,

June 26,

June 27,

2021

2020

2021

2020
Basic

140,358

142,350

141,316

142,654
Effect of dilutive securities:

Stock options, restricted stock and restricted stock units

1,299

0

1,222

0

Diluted

141,657

142,350

142,538

142,654
significant impact

on our comprehensive income.

The

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

~~Note 13 – Income Taxes~~

~~For~~foreign currency translation loss during the ~~six~~three months ended ~~June~~ March

26, ~~2021 our effective tax rate was 24.3% compared to 24.2% for the prior year period.~~ ~~The difference between our effective tax rates~~2022 and ~~the federal statutory tax rate for the six~~three months ended ~~June 26, 2021~~ primarily relates to state and foreign income taxes, interest expense and tax charges and credits associated with legal entity reorganizations. The difference between our effective tax rate and the federal statutory tax rate for the ~~six~~ ~~months ended~~ ~~June 27, 2020~~ primarily relates to state and foreign income taxes and interest expense, tax charges and credits associated with legal entity reorganizations outside the U.S and a valuation allowance recognized on a portion of a deferred tax asset.

The American Rescue Plan Act of 2021 (“ARPA”) was signed into law on March 11, 2021. The ARPA included a corporate income tax provision to further limit the deductibility of compensation under Section 162(m) for tax years starting after December 31, 2026. Section 162(m) generally limits the deductibility of compensation paid to covered employees of publicly held corporations. Covered employees include the CEO, CFO and the three highest paid officers. The ARPA expands the group of covered employees to additionally include five of the highest paid employees.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act includes, but is not limited to, certain income tax provisions that modify the Section 163(j) limitation of business interest and net operating loss carryover and carryback rules. We have analyzed the income tax provisions of the CARES Act and have accounted for the impact in the six months ended June 27, 2020, which did not have a material impact on our consolidated financial statements. There are certain other non-income tax benefits available to us under the CARES Act that require further clarification or interpretation that may affect our consolidated financial statements in the future.

~~The total amount of unrecognized tax benefits, which are included in “Other liabilities” within our consolidated balance sheets, as of June 26,~~

2021 was approximately $79.3 million, of which $63.9 million would affect the effective tax rate if recognized. It is possible that the amount of unrecognized tax benefits will change in the next 12 months, which may result in a material impact on our consolidated statements of income.

~~The tax years subject to examination~~primarily impacted by major tax jurisdictions include years 2017 and forward by the U.S Internal Revenue Service (the “IRS”) as well as the years 2008 and forward for certain states and certain foreign jurisdictions. All tax returns audited by the IRS are officially closed through 2016. During the quarter ended June 26, 2021 we reached a resolution with the Appellate Division for all remaining outstanding issues for 2012 and 2013. The resolution did not have a material impact to our consolidated financial statements. We reached a settlement with the U.S. Competent Authority to resolve certain transfer pricing issues related to 2012 and 2013 in the quarter ended December 28, 2019. During the quarter ended September 26, 2020 we finalized negotiations with the Advance Pricing Division and reached an agreement on an appropriate transfer pricing methodology for the years 2014-2025. The objective of this resolution was to mitigate future transfer pricing audit adjustments. In the fourth quarter of 2020, we reached a favorable resolution with the IRS relating to select audit years.

The total amounts of interest and penalties are classified as a component of the provision for income taxes. The amount of tax interest expense/(credit) was approximately $(2.7) million for the six months ended June 26, 2021, and $1.8 million for the six months ended June 27, 2020. The total amount of accrued interest is included in “Other liabilities,” and was approximately $11.3 million as of June 26, 2021 and $14.0 million as of December 26, 2020. NaN penalties were accrued for the periods presented.

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

~~Note 14~~ – ~~Derivatives and Hedging Activities~~

~~We are exposed to market risks as well as~~ changes in foreign currency exchange rates ~~as measured against the U.S. dollar and each other, and changes to the credit risk~~

of the ~~derivative counterparties. We attempt to minimize these risks by primarily using foreign currency forward contracts~~Euro, British Pound, Brazilian

Real, Australian Dollar and by maintaining counter-party credit limits. These hedging activities provide only limited protection against currency exchange and credit risks. Factors that could influence the effectiveness of our hedging programs include currency markets and availability of hedging instruments and liquidity of the credit markets. All foreign currency forward contracts that we enter into are components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by diversifying our counterparties, maintaining a strong balance sheet and having multiple sources of capital.

~~During 2019~~ ~~we entered into~~ foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges. These net investment hedges offset the change in the U.S dollar value of our investment in certain euro-functional currency subsidiaries due to fluctuating foreign exchange rates. ~~Gains and losses related to these net investment hedges are recorded in~~ Accumulated other comprehensive loss within our consolidated balance sheets. Amounts excluded from the assessment of hedge effectiveness are included in interest expense within our consolidated statements of income. The aggregate notional value of this net investment hedge, which matures on November 16, 2023, is approximately €200 million. During the three months ended June 26, 2021 and June 27, 2020, we recognized approximately $1.1 million and $1.2 million, respectively, of interest savings as a result of this net investment hedge. During the six months ended June 26, 2021 and June 27, 2020, we recognized approximately $2.2 and $2.4 million, respectively, of interest savings as a result of this net investment hedge.

On March 20, 2020, we entered into a total return swap for the purpose of economically hedging our unfunded non-qualified supplemental retirement plan (“SERP”) and our deferred compensation plan (“DCP”). This swap will offset changes in our SERP and DCP liabilities. At the inception, the notional value of the investments in these plans was $43.4 million. At June 26, 2021, the notional value of the investments in these plans was $84.8 million. At June 26, 2021, the financing blended rate for this swap was based on LIBOR of 0.09% plus 0.47%, for a combined rate of 0.56%. For the three months and six months ended June 26, 2021, we have recorded a gain, within the selling, general and administrative line item in our consolidated statement of income, of approximately $5.4 million and $8.1 million, respectively, net of transaction costs, related to this undesignated swap. For the three months and six months ended June 27, 2020, we have recorded a gain, within the selling, general and administrative line item in our consolidated statement of income, of approximately $6.7 million and $10.3 million, respectively, net of transaction costs, related to this undesignated swap. This swap is expected to be renewed on an annual basis after its current expiration date of March 29, 2022, and is expected to result in a neutral impact to our results of operations.

Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or negatively affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase short-term (i.e., generally 18 months or less) foreign currency forward contracts to protect against currency exchange risks associated with intercompany loans due from our international subsidiaries and the payment of merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into U.S. dollars, as we regard this as an accounting exposure, not an economic exposure. Our hedging activities have historically not had a material impact on our consolidated financial statements. Accordingly, additional disclosures related to derivatives and hedging activities required by ASC 815 have been omitted.

Canadian Dollar.

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

~~Note 15 – Stock-Based Compensation~~

Our accompanying consolidated statements of income reflect pre-tax share-based compensation expense of $17.4 million ($13.3 million after-tax) and $30.2 million ($22.8 million after-tax) for the three and six months ended June 26, 2021, respectively. For the three and six months ended June 27, 2020 we recorded pre-tax share-based compensation expense of $5.2 million ($4.2 million after-tax) and a credit of $12.4 million ($9.4 million after-tax), respectively. The $12.4 million credit for share-based compensation during the six months ended June 27, 2020 reflected our reduced estimate in expected achievement of performance-based targets resulting from the impact of COVID-19.

Our accompanying consolidated statements of cash flows present our stock-based compensation expense (credit) as an adjustment to reconcile net income to net cash provided by operating activities for all periods presented. In the accompanying consolidated statements of cash flows, there were 0 benefits associated with tax deductions in excess of recognized compensation as a cash inflow from financing activities for the six months ended June 26, 2021 and June 27, 2020, respectively.

Stock-based compensation represents the cost related to stock-based awards granted to employees and non-employee directors. We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and recognize the cost (net of estimated forfeitures) as compensation expense over the requisite service period. Our stock-based compensation expense is reflected in selling, general and administrative expenses in our consolidated statements of income.

Stock-based awards are provided to certain employees and non-employee directors under the terms of our 2020 Stock Incentive Plan and our 2015 Non-Employee Director Stock Incentive Plan (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors (the “Compensation Committee”). Historically, equity-based awards have been granted solely in the form of restricted stock units (“RSUs”). However, beginning in 2021, our equity-based awards have been granted in the form of RSUs and non-qualified stock options.

Grants of RSUs are stock-based awards granted to recipients with specified vesting provisions. In the case of RSUs, common stock is generally delivered on or following satisfaction of vesting conditions. We issue RSUs that vest solely based on the recipient’s continued service over time (primarily four-year cliff vesting, except for grants made under the 2015 Non-Employee Director Stock Incentive Plan, which are primarily 12-month cliff vesting), and RSUs that vest based on our achieving specified performance measurements and the recipient’s continued service over time (primarily ~~three-year~~ ~~cliff vesting). For these RSUs, we recognize the cost as compensation expense on a straight-line basis.~~

During the three months ended March 27, 2021, as a result of the continuing economic risk and uncertainty resulting from the ongoing COVID-19 pandemic, the Compensation Committee decided to adjust the form of awards granted under our 2021 long-term incentive program for our 2021 fiscal year in a manner that focuses on our long-term value by granting stock options and time-based RSUs rather than performance-based RSUs. Stock options are awards that allow the recipient to purchase shares of our common stock at a fixed price following vesting of the stock options. Stock options are granted at an exercise price equal to our closing stock price on the date of grant. Stock options issued during 2021 vest ~~one-third~~ ~~per year based on the recipient’s continued service, subject to the terms and conditions of the Plans, are fully vested~~ three years from the grant date and have a contractual term of ten years from the grant date, subject to earlier termination of the term upon certain events. Compensation expense for these stock options is recognized using a graded vesting method. We estimate the fair value of stock options using the Black-Scholes valuation model.

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

In addition to equity-based awards under the 2021 long-term incentive program under the 2020 Stock Incentive Plan, the Compensation Committee granted a Special Pandemic Recognition Award under the 2020 Stock Incentive Plan to recipients of performance-based RSUs under the 2018 long-term incentive program. These awards will vest 50% on the first anniversary of the grant date and 50% on the second anniversary of the grant date and are recorded as compensation expense using a graded vesting method.

With respect to time-based RSUs, we estimate the fair value on the date of grant based on our closing stock price at time of grant. With respect to performance-based RSUs, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based RSUs based on our closing stock price at time of grant.

The Plans provide for adjustments to the performance-based restricted stock units targets for significant events, including, without limitation, acquisitions, divestitures, new business ventures, certain capital transactions (including share repurchases), restructuring costs, if any, certain litigation settlements or payments, if any, changes in accounting principles or in applicable laws or regulations, changes in income tax rates in certain markets and foreign exchange fluctuations. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on our actual performance metrics as defined under the Plans.

~~Total unrecognized compensation cost related to unvested awards as of June 26, 2021 was $99.0 million, which is expected to be recognized over a weighted-average period of approximately 2.5 years.~~

~~The following weighted-average assumptions were used in determining the most recent fair values of stock options using the Black-Scholes valuation model:~~


~~Expected dividend yield~~	~~0.0~~	%
~~Expected stock price volatility~~	~~26.60~~	%
~~Risk-free interest rate~~	~~0.94~~	%
~~Expected life of options (years)~~	~~6.00~~

We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in the foreseeable future. The expected stock price volatility is based on implied volatilities from traded options on our stock, historical volatility of our stock, and other factors. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant in conjunction with considering the expected life of options. The 6-year expected life of the options was determined using the simplified method for estimating the expected term as permitted under SAB Topic 14. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by recipients of stock options, and subsequent events are not indicative of the reasonableness of the original estimates of fair value made by us.

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

The following table summarizes ~~stock option activity under the Plans during the six months ended June 26, 2021:~~

Weighted

Average

Weighted

Remaining

Average

Contractual

Aggregate

Exercise

Life in

Intrinsic

Shares

Price

Years

Value
Outstanding at beginning of period

0

$
0

Granted

794

62.82

Exercised

0

0

Forfeited

(2)

62.71

Outstanding at end of period

792

$
62.82

9.7

$
12.21

Options exercisable at end of period

1

$
0

-

$
0

~~The following tables summarize the activity of~~ our ~~unvested RSUs for the six months ended June 26, 2021:~~

Time-Based Restricted Stock Units

Weighted Average

Grant Date Fair

Intrinsic Value

Shares/Units

Value Per Share

Per Share
Outstanding at beginning of period

1,459

$
57.61

Granted

821

63.02

Vested

(266)

66.85

Forfeited

(19)

60.47

Outstanding at end of period

1,995

$
58.64

$
75.01

Performance-Based Restricted Stock Units

Weighted Average

Grant Date Fair

Intrinsic Value

Shares/Units

Value Per Share

Per Share
Outstanding at beginning of period

136

$
53.52

Granted

286

58.60

Vested

(83)

52.30

Forfeited

(9)

59.46

Outstanding at end of period

330

$
59.50

$
75.01

~~Note 16 – Supplemental Cash Flow Information~~

~~Cash paid for interest and~~total comprehensive income, net of

applicable taxes, ~~was:~~

Six Months Ended

June 26,

June 27,

2021

2020
Interest

$
13,605

$
16,925
Income taxes

134,232

31,553

as follows:

~~During the six months ended June 26, 2021 and June 27, 2020, we had a $2.3 million and $13.5 million of non-cash net unrealized gains related to foreign currency hedging activities, respectively.~~

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

Three Months Ended

March 26,

March 27,

2022

2021

Comprehensive income attributable to

Henry Schein, Inc.

184

138

Comprehensive income attributable to

noncontrolling interests

Comprehensive income attributable to

Redeemable noncontrolling interests

Comprehensive income

190

141

Note 1713 – ~~Legal Proceedings~~

Plans of Restructuring

On ~~August 31, 2012~~, ~~Archer~~November 20, 2019, we committed to a contemplated restructuring

initiative intended to mitigate stranded costs

associated with the spin-off of our animal health business and ~~White Sales, Inc. (“Archer”~~to rationalize operations

and to provide expense

efficiencies.

These restructuring activities were completed in 2021.

During the three months ended March 27, 2021, we recorded restructuring

costs of $

million.

As of March 26,

2022 and December 25, 2021, the remaining accrued balance for restructuring

costs was $

million and $

million,

respectively

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in millions, except share and per share data)

(unaudited

) ~~filed a complaint against~~

Note 14

–

Earnings Per Share

Basic earnings per share is computed by dividing net income attributable

to Henry Schein, Inc. ~~as well as Danaher Corporation and its subsidiaries Instrumentarium Dental, Inc., Dental Equipment, LLC, Kavo Dental Technologies, LLC and Dental Imaging Technologies Corporation (collectively,~~by the ~~“Danaher Defendants”) in the U.S. District Court~~weighted-

average number of common shares outstanding for the ~~Eastern District~~period.

Our diluted earnings per share is computed similarly

to basic earnings per share, except that it reflects the effect of ~~Texas, Civil Action No. 2:12-CV-00572-JRG, styled~~ common shares issuable

for presently unvested

restricted stock and RSUs and upon exercise of stock options using

the treasury stock method in periods in which

they have a dilutive effect.

A reconciliation of shares used in calculating earnings per basic and

diluted share follows:

Three Months Ended

March 26,

March 27,

2022

2021

Basic

137,296,581

142,298,387

Effect of dilutive securities:

Stock options, restricted stock and restricted stock units

1,940,891

1,099,337

Diluted

139,237,472

143,397,724

The effect of weighted average assumed exercise of stock options outstanding totaling

76,597

and

216,482

as ~~an antitrust action under Section 1~~of

March 26, 2022 and March 27, 2021, respectively, were excluded from the calculation of diluted weighted average

common shares outstanding because the ~~Sherman Act,~~effect would have been antidilutive.

The effect of weighted average non-vested restricted stock units outstanding totaling

70,923

and

6,315

as of March

26, 2022 and March 27, 2021,

respectively, were excluded from the ~~Texas Free Enterprise Antitrust Act. Archer alleged a conspiracy between Henry Schein, an unnamed company and~~calculation of diluted weighted average

common shares outstanding because the ~~Danaher Defendants to terminate or limit Archer’s distribution rights. On~~ ~~August 1, 2017~~, Archer filed an amended complaint, adding Patterson Companies, Inc. (“Patterson”) and Benco Dental Supply Co. (“Benco”) as defendants, and alleging that Henry Schein, Patterson, Benco and Burkhart Dental Supply conspired to fix prices and refused to compete with each othereffect would have been antidilutive.

Note 15 – Supplemental Cash Flow Information

Cash paid for sales of dental equipment to dental professionals and agreed to enlist their common suppliers, the Danaher Defendants, to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually terminating, their price-cutting competing distributor Archer. Archer sought damages in an amount to be proved at trial, to be trebled with interest and ~~costs, including attorneys’ fees, jointly~~income taxes was:

Three Months Ended

March 26,

March 27,

2022

2021

Interest

Income taxes

During the three months ended March 26, 2022 and ~~severally, as well as injunctive relief. On~~ ~~October 30, 2017~~, ~~Archer filed~~March 27, 2021,

we had a ~~second amended complaint,~~$

million and a $

million of non-

cash net unrealized gains related to ~~add additional allegations that it believes support its claims. The named parties and causes of action were the same as the August 1, 2017 amended complaint.~~

On October 1, 2012, we filed a motion for an order: (i) compelling Archer to arbitrate its claims against us; (2) staying all proceedings pending arbitration; and (3) joining the Danaher Defendants’ motion to arbitrate and stay. On May 28, 2013, the Magistrate Judge granted the motions to arbitrate and stayed proceedings pending arbitration. On June 10, 2013, Archer moved for reconsideration before the District Court judge. On December 7, 2016, the District Court Judge granted Archer’s motion for reconsideration and lifted the stay. Defendants appealed the District Court’s order. On December 21, 2017, the U.S. Court of Appeals for the Fifth Circuit affirmed the District Court’s order denying the motions to compel arbitration. On June 25, 2018, the Supreme Court of the United States granted defendants’ petition for writ of certiorari. On October 29, 2018, the Supreme Court heard oral arguments. On January 8, 2019, the Supreme Court issued its published decision vacating the judgment of the Fifth Circuit and remanding the case to the Fifth Circuit for further proceedings consistent with the Supreme Court’s opinion. On April 2, 2019, the District Court stayed the proceeding in the trial court pending resolution by the Fifth Circuit. The Fifth Circuit heard oral argument on May 1, 2019 on whether the case should be arbitrated. The Fifth Circuit issued its opinion on August 14, 2019 affirming the District Court’s order denying defendants’ motions to compel arbitration. Defendants filed a petition for rehearing en banc before the Fifth Circuit. The Fifth Circuit denied that petition. On October 1, 2019, the District Court set the case for trial on February 3, 2020, which was subsequently moved to January 29, 2020. On January 24, 2020 the Supreme Court granted our motion to stay the District Court proceedings, pending the disposition of our petition for writ of certiorari, which was filed on January 31, 2020. Archer conditionally cross petitioned for certiorari on an arbitration issue on March 2, 2020. On June 15, 2020, the Supreme Court granted our petition for writ of certiorari, and denied Archer’s conditional petition for certiorari, and thus the District Court proceedings remained stayed. After briefing from the parties and several amici, the case was argued before the Supreme Court on December 8, 2020. On January 25, 2021, the Supreme Court dismissed the writ of certiorari as improvidently granted. That action dissolved the stay the Supreme Court had previously granted. The U.S. District Court for the Eastern District of Texas then set the case for trial, and jury selection was scheduled to begin on June 1, 2021. Patterson and the Danaher Defendants settled with Archer and they have been dismissed from the case with prejudice. Benco settled

foreign currency hedging activities,

respectively.

HENRY SCHEIN, INC.

NOTES TO CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

(in ~~thousands,~~millions, except share and per share data)

(unaudited)

~~the case with the plaintiff. Henry Schein and the plaintiff settled this matter for an amount that is not material to the Company. The court dismissed the case with prejudice on May 25, 2021.~~

On ~~May 29, 2018, an amended complaint was filed in the MultiDistrict Litigation (“MDL”~~) ~~proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) in an action entitled~~ The County of Summit, Ohio et al. v. Purdue Pharma, L.P., et al., Civil Action No. 1:18-op-45090-DAP (“County of Summit Action”), in the U.S. District Court for the Northern District of Ohio, adding Henry Schein, Inc., Henry Schein Medical Systems, Inc. and others as defendants. Summit County alleged that manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and Henry Schein Medical Systems, Inc.) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. ~~On October 29, 2019, the Company was dismissed with prejudice from this lawsuit. Henry Schein, working with Summit County, donated $1 million to a foundation and paid $250,000 of Summit County’s expenses, as described in our prior filings with the SEC.~~

In addition to the County of Summit Action, Henry Schein and/or one or more of its affiliated companies have been named as a defendant in multiple lawsuits (currently less than one-hundred and fifty (150)), which allege claims similar to those alleged in the County of Summit Action. These actions consist of some that have been consolidated within the MDL and are currently abated for discovery purposes, and others which remain pending in state courts and are proceeding independently and outside of the MDL. On October 9, 2020, the Circuit Court of the 17th Judicial Circuit in and for Broward County, Florida, Case No. CACE19018882, granted Henry Schein’s motion to dismiss the claims brought against it in the action filed by North Broward Hospital District et. al. The Florida court gave plaintiffs until November 24, 2020 to replead their claims against Henry Schein. On January 8, 2021, Henry Schein filed a motion to dismiss the Amended Complaint. By Order entered on March 24, 2021, the Circuit Court of Washington County, Arkansas, Case No. 72-CV20-156, granted Henry Schein’s motion to dismiss the claims brought against it in the action filed by Fayetteville Arkansas Hospital Company, LLC, et al. The Arkansas plaintiffs filed an amended complaint on July 29, 2021and did not name Henry Schein as a defendant. An action filed by Tucson Medical Center et al. was previously scheduled for trial beginning on June 1, 2021 but the court has vacated that trial date. At this time, the only cases set for trial are the actions filed by West Virginia University Hospitals, Inc. et al., which is currently scheduled for a non-jury liability trial on plaintiffs’ public nuisance claims on November 1, 2021, and DCH Health Care Authority, et al., which is currently scheduled for a liability jury trial on plaintiffs’ public nuisance claims on July 18, 2022. Of Henry Schein’s 2020 revenue of approximately $10.1 billion from continuing operations, sales of opioids represented less than ~~one-tenth of 1~~ ~~percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions.~~

On ~~September 30, 2019, the~~ City of Hollywood Police Officers Retirement System, individually and on behalf of all others similarly situated, filed a putative class action complaint for violation of the federal securities laws against Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola (Covetrus’s then Chief Executive Officer and Chief Financial Officer, respectively) in the U.S. District Court for the Eastern District of New York, Case No. 2:19-cv-05530-FB-RLM. The complaint seeks to certify a class consisting of all persons and entities who, subject to certain exclusions, purchased or otherwise acquired Covetrus common stock from February 8, 2019 through August 12, 2019. The case relates to the Animal Health Spin-off and Merger of the Henry Schein Animal Health Business with Vets First Choice in February 2019. The complaint alleges violations of Sections 10(b) and 20(a) of the

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

~~Securities Exchange Act of 1934,~~ ~~as amended, and Securities and Exchange Commission Rule 10b-5 and asserts that defendants’ statements in the offering documents and after the transaction were materially false and misleading~~ because they purportedly overstated Covetrus’s capabilities as to inventory management and supply-chain services, understated the costs of integrating the Henry Schein Animal Health Business and Vets First Choice, understated Covetrus’s separation costs from Henry Schein, and understated the impact on earnings from online competition and alternative distribution channels and from the loss of an allegedly large customer in North America just before the Separation and Merger. The complaint seeks unspecified monetary damages and a jury trial. Pursuant to the provisions of the PSLRA, the court appointed lead plaintiff and lead counsel on December 23, 2019. Lead plaintiff filed a Consolidated Class Action Complaint on February 21, 2020. Lead plaintiff added Steve Paladino, our Chief Financial Officer, as a defendant in the action. Lead plaintiff filed an Amended Consolidated Class Action Complaint on May 21, 2020, in which it added a claim that Mr. Paladino is a “control person” of Covetrus. We intend to defend ourselves vigorously against this action.

On ~~February 5, 2021~~, Jack Garnsey filed a putative shareholder derivative action on behalf of Covetrus, Inc. in the U.S. District Court for the Eastern District of New York, naming as defendants Benjamin Shaw, Christine T. Komola, Steven Paladino, Betsy Atkins, Deborah G. Ellinger, Sandra L. Helton, Philip A. Laskaway, Mark J. Manoff, Edward M. McNamara, Ravi Sachdev, David E. Shaw, Benjamin Wolin, and Henry Schein, Inc., with Covetrus, Inc. named as a nominal defendant. The complaint alleges that the individual defendants breached their fiduciary duties under state law in connection with the same allegations asserted in the City of Hollywood securities class action described above and further alleges that Henry Schein aided and abetted such breaches. The complaint also asserts claims for contribution under the federal securities laws against Henry Schein and other defendants, also arising out of the allegations in the City of Hollywood lawsuit. The complaint seeks declaratory, injunctive, and monetary relief. We intend to defend ourselves vigorously against this action. On April 8, 2021 the Court entered an order staying the Garnsey action until forty-five (45) days after a decision is issued finally resolving the motions to dismiss in the City of Hollywood Class Action.

From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations.

As of June 26, 2021, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

Note 1816 – Related Party Transactions

On February 7, 2019 (the “Distribution Date”), we completed the separation (the “Separation”) and subsequent merger (“Merger”) of our animal health business (the “Henry Schein Animal Health Business”) with Direct Vet Marketing, Inc. (d/b/a Vets First Choice, “Vets First Choice”). This was accomplished by a series of transactions among us, Vets First Choice, Covetrus, Inc. (f/k/a HS Spinco, Inc. “Covetrus”), a wholly owned subsidiary of ours

~~HENRY SCHEIN, INC.~~

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~

~~(in thousands, except per share data)~~

~~(unaudited~~)

prior to the Distribution Date, and HS Merger Sub, Inc., a wholly owned subsidiary of Covetrus. In connection with the Separation, we contributed, assigned and transferred to Covetrus certain applicable assets, liabilities and capital stock or other ownership interests relating to the Henry Schein Animal Health Business. On the Distribution Date, we received a tax-free distribution of $1,120 million from Covetrus pursuant to certain debt financing incurred by Covetrus. On the Distribution Date and prior to the Animal Health Spin-off, Covetrus issued shares of Covetrus common stock to certain institutional accredited investors for $361.1 million (the “Share Sale”). The proceeds of the Share Sale were paid to Covetrus and distributed to us. Subsequent to the Share Sale, we distributed, on a pro rata basis, all of the shares of the common stock of Covetrus held by us to our stockholders of record as of the close of business on January 17, 2019 (the “Animal Health Spin-off”).

In connection with the completion of the Animal Health Spin-off during our 2019 fiscal year, we entered into a transition services agreement with Covetrus under which we agreed to provide certain transition services for up to twenty-four months in areas such as information technology, finance and accounting, human resources, supply chain, and real estate and facility services. Services provided under this transition services agreement ended in December 2020. During the three and six months ended June 27, 2020, we recorded approximately $4.3 million and $8.8 million, respectively, of fees for these services. Covetrus also purchased certain products from us pursuant to the transition services agreement, which ended in December 2020. During the three and six months ended June 27, 2020, net sales to Covetrus were approximately $20.1 million and $41.2 million, respectively.

In connection with the formation of Henry Schein One, LLC, our joint venture

with Internet Brands, which was

formed on July 1, 2018, we entered into a

ten-year

royalty agreement with Internet Brands whereby we will pay

Internet Brands approximately $~~31.0~~

million annually for the use of their intellectual property.

During the three ~~and six~~

months ended ~~June~~March 26, 2022 and March 27, 2021, we recorded $~~7.8~~

million and ~~$15.6~~ $

million, respectively, in

connection with costs related to this royalty agreement. ~~During the three and six months ended June 27, 2020, we recorded $7.8 million and $15.6 million, respectively in connection with costs related to this royalty agreement.~~

As of ~~June~~March 26, ~~2021~~2022 and December ~~26, 2020,~~25, 2021, Henry

Schein One, LLC had a net ~~(payable)~~ receivable balance due ~~(to)~~ from Internet Brands of ~~$(6.3)~~

million and ~~$4.7~~ $

million, respectively,

comprised of amounts related to results of operations and the royalty agreement.

During our normal course of business, we have interests in entities that we

account for under the equity accounting

method.

During the three ~~and six~~ months ended ~~June~~March 26, 2022 and March 27,

2021, we recorded net sales of ~~$18.0~~ $

million

and ~~$33.4~~ $

million, respectively, to such entities.

During the three ~~and six~~ months ended ~~June~~March 26, 2022 and March 27, ~~2020,~~

2021,

we ~~recorded net sales of $9.1~~ purchased $

million and ~~$24.5 million, respectively, to such entities. During the three and six months ended June 26, 2021, we purchased $5.3 million and $9.1~~ $

million, respectively from such entities. ~~During the three~~

At March 26, 2022 and ~~six months ended June 27, 2020,~~December 25,

2021, we ~~purchased $1.7~~ had in aggregate $

million and ~~$4.5 million, respectively, from such entities. At June 26, 2021 and December 26, 2020, in the aggregate we had $42.0 million and $36.4~~ $

million, due from our equity affiliates, and ~~$10.1~~ $

million and ~~$8.6~~ $

million due to our equity affiliates, respectively.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND

RESULTS OF OPERATIONS

Cautionary Note Regarding Forward-Looking Statements

In accordance with the “Safe Harbor” provisions of the Private Securities

Litigation Reform Act of 1995, we

provide the following cautionary remarks regarding important factors

that, among others, could cause future results

to differ materially from the forward-looking statements, expectations and assumptions

expressed or implied

herein.

All forward-looking statements made by us are subject to

risks and uncertainties and are not guarantees of

future performance.

These forward-looking statements involve known and unknown

risks, uncertainties and other

factors that may cause our actual results, performance and achievements

or industry results to be materially

different from any future results, performance or achievements expressed or implied by such

forward-looking

statements.

These statements are generally identified by the use of such

terms as “may,” “could,” “expect,” ~~“intend,~~

“intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” ~~“to~~

“to be,” “to make” or other comparable

terms.

Factors that could cause or contribute to such differences include, but are not limited

to, those discussed in

the documents we file with the Securities and Exchange Commission

(SEC), including our Annual Report on Form

10-K. Forward looking statements include the overall impact of the Novel

Coronavirus Disease 2019 (COVID-19)

on the Company, its results of operations, liquidity and financial condition (including any estimates of the impact

on these items), the rate and consistency with which dental and other practices

resume or maintain normal

operations in the United States and internationally, expectations regarding personal protective equipment (“PPE”)

and COVID-19 related product sales and inventory levels, ~~and~~ whether additional

resurgences or variants of the virus

will adversely impact the resumption of normal operations, whether vaccine

mandates will adversely impact the

Company (by disrupting our workforce and/or business), whether supply chain

disruptions will adversely impact

our business, the impact of restructuring programs as well as of any

future acquisitions, and more generally current

expectations regarding performance in current and future periods.

Forward looking statements also include the (i)

ability of the Company to ~~make additional testing available, the nature~~have continued access to a variety of ~~those tests~~COVID-19

test types, expectations regarding

COVID-19 test sales, demand and ~~the number of tests intended to be made available and the timing for availability, the nature of the target market,~~inventory levels, as well

as the efficacy or relative efficacy of the test results

given that the test efficacy has not been, or will not have been, independently

verified under normal FDA

procedures and (ii) potential for the Company to distribute the COVID-19

vaccines and ancillary supplies.

Risk factors and uncertainties that could cause actual results to differ materially from current

and historical results

include, but are not limited to: risks associated with COVID-19

and any variants thereof, as well as other disease

outbreaks, epidemics, pandemics, or similar ~~wide spread~~wide-spread public health concerns

and other natural ~~disasters or acts of terrorism;~~disasters; our

dependence on third parties for the manufacture and supply of our products;

our ability to develop or acquire and

maintain and protect new products (particularly technology products) and

technologies that achieve market

acceptance with acceptable margins; transitional challenges associated with acquisitions,

dispositions and joint

ventures, including the failure to achieve anticipated synergies/benefits; financial

and tax risks associated with

acquisitions, dispositions and joint ventures; certain provisions in our governing

documents that may discourage

third-party acquisitions of us; effects of a highly competitive (including, without

limitation, competition from ~~third-party~~third-

party online commerce sites) and consolidating market; the ~~potential~~ repeal or

judicial prohibition on implementation of the

Affordable Care Act; changes in the health care industry; risks from expansion of

customer purchasing power and

multi-tiered costing structures; increases in shipping costs for our products

or other service issues with our ~~third-party~~third-

party shippers; general global macro-economic and political conditions,

including international trade agreements, ~~and~~

potential trade ~~barriers;~~barriers and terrorism; failure to comply with existing and

future regulatory requirements; risks

associated with the EU Medical Device Regulation; failure to comply with

laws and regulations relating to health

care fraud or other laws and regulations; failure to comply with laws

and regulations relating to the ~~confidentiality~~collection,

storage and processing of sensitive personal information or standards in electronic

health records or transmissions;

changes in tax legislation; risks related to product liability, intellectual property and other claims; litigation

risks; new or unanticipated litigation developments and the status of

litigation matters; risks associated with

customs policies or legislative import restrictions; cyberattacks or other

privacy or data security breaches; risks

associated with our global operations; our dependence on our senior management, ~~as well as~~

employee hiring and ~~retention;~~ retention,

and our relationships with customers, suppliers and manufacturers;

and disruptions in financial markets.

The order

in which these factors appear should not be construed to indicate their

relative importance or priority.